AU2009279471A1 - Treatment of autoimmune and inflammatory disease - Google Patents

Description

WO 2010/017468 PCT/US2009/053136 Treatment of Autoimmune and Inflammatory Disease The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases, and novel isolated binding proteins for use in these 5 methods. There is also provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 or IL-7R. Background of the invention Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating disease that 10 affects the central nervous system. In MS, it is believed that infiltrating inflammatory immune cells are involved in the destruction of oligodendrocytes, which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath. MS results in the thinning or complete loss of myelin. When the myelin is lost, the neurons can no longer effectively conduct their electrical signals leading to numerous neurologic 15 dysfunctions. Individuals with MS produce autoreactive T cells that participate in the formation of inflammatory lesions along the myelin sheath of nerve fibres. The cerebrospinal fluid of patients with active MS contains activated T cells, which infiltrate the brain tissue and cause characteristic inflammatory lesions, destroying the myelin. While the multiple sclerosis symptoms and course of illness can vary from person to 20 person, there are three forms of the disease-relapsing-remitting MS, secondary progressive MS, and primary progressive MS. In the early stages of MS, inflammatory attacks occur over short intervals of acutely heightened disease activity. These episodes are followed by periods of recovery and remission. During the remission period, the local swelling in the nervous system 25 lesion resolves, the immune cells become less active or inactive, and the myelin producing cells remyelinate the axons. Nerve signalling improves, and the disability caused by the inflammation becomes less severe or goes away entirely. This phase of the disease is called relapsing-remitting MS (RRMS). The lesions do not all heal completely, though. Some remain as "chronic" lesions, which usually have a 30 demyelinated core region which lacks immune cells. Over time, the cells in the centre of such lesions mostly die, although inflammation often continues at their edges. The brain can adapt well to the loss of some neurons, and permanent disability may not occur for many years. However, more than 50% of patients with MS eventually enter a stage of progressive deterioration, called secondary progressive MS (SPMS). In this stage, the 35 disease no longer responds well to disease-modifying drugs, and patients' disabilities steadily worsen. The destruction of neurons from early in the natural course of MS 1 WO 2010/017468 PCT/US2009/053136 suggests that the progressive disabilities of SPMS might be the result of an accumulated neuronal loss that eventually overwhelms the brain's compensatory abilities. Primary progressive MS is a type of multiple sclerosis where there are no relapses, but over a period of years, there is gradual loss of physical and cognitive functions. 5 The goal of treatment in patients with relapsing-remitting multiple sclerosis is to reduce the frequency and severity of relapses (and thereby prevent exacerbations) as well as to prevent or postpone the onset of the progressive phase of the disease. To achieve this goal, in the past especially, immunomodulatory or immunosuppressive drugs have been used, but they have never found widespread acceptance owing to limited 10 efficacy and considerable toxicity. For example, large randomized controlled trials have been performed successfully with interferon beta-la, interferon beta-1b, and glatiramer acetate. Both altered autoimmune T cell responses and dysfunction of the regulatory network of the immune system play an important role in human autoimmune pathologies, 15 such as MS and rheumatoid arthritis (Kuchroo et al., (2002) Annu. Rev. Immunol. 20:101 123; Sospedra and Martin (2005) Annu. Rev. Immunol. 23: 683-747; Toh and Miossec (2007) Curr. Opin. Rheumatol. 19:284-288). Although the aetiology and pathogenesis of MS remain unknown, it is generally considered an autoimmune pathology in which autoreactive T cells of pathogenic 20 potential, such as TH1 and TH1 7 cells, are thought to play an important role. There is evidence that these effector T cells are activated in vivo during the disease process and are attributable to the central nervous system (CNS) inflammation. There is also evidence that these T cells mediate destruction of myelin-expressing cells in lesions of EAE and MS during the active phase of the disease. On the other hand, regulatory T 25 cells (Treg) that normally keep pathogenic TH1 and TH1 7 cells in check are deficient in patients with MS, further tilting the immune system toward an pro-inflammatory state. Three separate groups recently reported the results of genome wide single nucleotide polymorphisms (SNPs) scanning in a total of 17,947 donors with or without MS. After scanning 334,923 SNPs, they found a highly significant association (overall 30 P=2.9x10-7) of a nonsynonymous coding SNP in the human IL-7 receptor alpha chain (IL 7Ra) with MS susceptibility. The SNP corresponds to a change from T to C in exon 6 of CD127 (also known as IL-7Ra). This change enhances the chance of exon 6 skipping during RNA splicing, resulting in a soluble form of CD127. Furthermore, expressions of CD127 and IL-7 RNAs in the cerebrospinal fluids (CSFs) of MS patients are significantly 35 higher relative to CSFs of patients with other neurological disorders. 2 WO 2010/017468 PCT/US2009/053136 IL-7 and IL-7 receptor (IL-7R) are known to play an important role in T cell and B cell development and homeostasis mainly in a thymic environment. Indeed, thymic stromal cells, fetal thymus, and bone marrow are sites of IL-7 of production. The IL-7 receptor consists of two subunits, CD127 and a common chain (gamma chain or yc) 5 which is shared by receptors of IL-2, IL-4, IL-9, IL-15, and IL-21. CD127 is also known as IL-7 receptor alpha (IL-7Ra) and p90 IL-7R. Human CD127 (Swiss Prot accession number P16871) has a total of 459 amino acids (20 signal sequence). It comprises a 219 amino acid extra cellular region, a 25 amino acid transmembrane region and a 195 amino acid intracellular region. The numbering of 10 residues within CD127, as used herein (e.g. for the description of antibody epitopes) is based on the full length protein, including signal sequence residues. CD127 may exist in four isoforms, the isoform H20 (Swissprot accession number P16871-1) has the following amino acid sequence (including signal sequence): 15 MTILGTTFGM VFSLLQVVSG ESGYAQNGDL EDAELDDYSF SCYSQLEVNG SQHSLTCAFE DPDVNTTNLE FEICGALVEV KCLNFRKLQE IYFIETKKFL LIGKSNICVK VGEKSLTCKK IDLTTIVKPE APFDLSVIYR EGANDFVVTF NTSHLQKKYV KVLMHDVAYR QEKDENKWTH VNLSSTKLTL LQRKLQPAAM YEIKVRSIPD HYFKGFWSEW SPSYYFRTPE INNSSGEMDP ILLTISILSF FSVALLVILA CVLWKKRIKP IVWPSLPDHK KTLEHLCKKP RKNLNVSFNP 20 ESFLDCQIHR VDDIQARDEV EGFLQDTFPQ QLEESEKQRL GGDVQSPNCP SEDVVVTPES FGRDSSLTCL AGNVSACDAP ILSSSRSLDC RESGKNGPHV YQDLLLSLGT TNSTLPPPFS LQSGILTLNP VAQGQPILTS LGSNQEEAYV TMSSFYQNQ (SEQ ID NO: 1) CD127 is also found in the receptor of thymic stromal derived lymphopoietin 25 (TSLP). The TSLP receptor is a heterodimer of CD127 and cytokine receptor-like factor 2 (CRLF2). Binding of IL-7 to the IL-7R activates multiple signaling pathways including the activation of JAK kinases 1 and 3 leading to the phosphorylation and activation of Stat5. This pathway is crucial to the survival of thymic developing T cell precursors because 30 Stat5 activation is required in the induction of the anti-apoptotic protein Bcl-2 and the prevention of the pro-apoptotic protein Bax entry into the mitochondrion. Another IL-7R mediated pathway is the activation of P13 kinase, resulting in the phosphorylation of the pro-apoptotic protein Bad and its cytoplasm retention. CD127 is expressed in peripheral resting and memory T cells. The mechanism of IL-7 regulation of T cell survival and 35 homeostasis and the source of IL-7 in the periphery are not completely understood. Furthermore, its potential role in the differentiation and function of pathogenic T cells in 3 WO 2010/017468 PCT/US2009/053136 autoimmune disease is poorly studied and largely unknown. There are few reports suggesting that IL-7 may contribute to the pathogenesis of autoimmune diseases. CD127 has been described in W09015870 and antagonists of IL-7 and CD127 in the treatment of multiple sclerosis have been described in W02006052660 and 5 US20060198822. Antagonists of TSLP have been described in, for example, US7304144 and W02007096149. Summary of the Invention The present inventors have shown that IL-7/CD127 antagonism is efficacious in 10 amelioration of Experimental Autoimmune Encephalomyelitis (EAE). The treatment resulted in marked reduction of TH1 7 and, to a lesser degree, TH1 cells in both spleen and spinal cord of treated mice, which was accompanied by an increased level of Foxp3+ Treg. The inventors have also shown that IL-7 is critically required for the expansion and survival of TH1 7 cells, but that its requirement during differentiation of precursor T cells 15 into a TH1 7 cell population is minimal. Restoring the balance of the functional ratio of autoreactive inflammatory TH17 and TH1 cells and Treg with an antagonist of CD127 or IL-7 provides great potential as a therapy for multiple sclerosis and other autoimmune diseases. The selective susceptibility of TH17 and TH1 cells was attributable to high 20 expression of CD127 in activated pathogenic T cells and their requirement for IL-7 for expansion and survival. Blockade of CD127 led to altered signalling events characterized by down-regulation of phosphorylated JAK-1 and STAT-5 and BCL-2 and the increased activity of BAX, rendering CD127+ TH1 7 and TH1 cells susceptible to apoptosis. In contrast, Foxp3+ Treg (inducible Treg) were resistant to CD127 antagonism as they did not 25 express, or expressed lower levels of, CD127. Signalling events, including apoptotic pathways, downstream to IL-7/IL-7R interaction were not affected in Foxp3+ Treg by a neutralizing anti-CD127 antibody. Furthermore, similar effects of CD127 antagonism were seen in human TH1 7 and TH1 expansion and survival, which spared Treg. These findings provide new evidence supporting the role of IL-7 in pathogenic T cell 30 differentiation and maintenance and have important therapeutic implications in MS and other human autoimmune diseases. Therefore, in a first aspect of the invention, there is provided a method for the treatment of an autoimmune disease or an inflammatory disorder in a human subject, comprising administering to the subject an antagonist of at least one of: IL-7 receptor 35 mediated TH1 7 expansion, and IL-7 receptor mediated TH1 7 survival. 4 WO 2010/017468 PCT/US2009/053136 IL-7 receptor mediated TH1 7 expansion and/or survival can be observed at a cellular level by an increase or maintenance of TH1 7 cell count, or by an increase in the ratio of TH1 7 cell numbers compared to the numbers of other CD4+ T cells, or more specifically by an increase in the TH1 7 :TH1 ratio, the TH1 7 :Teg ratio, the (TH1 7 plus 5 TH ):Teg ratio, and/or the TH 7 :(TH1 plus Treg) ratio. At a molecular level, TH1 7 expansion and/or survival can be observed by an increase in IL-17 production by a population of CD4+ T cells (or by a population of TH17 cells). In an embodiment, therefore, the antagonist of IL-7 receptor mediated TH17 expansion and/or IL-7 receptor mediated TH1 7 survival reduces IL-17 production by a 10 population of CD4+ T cells. IL-7 receptor mediated TH1 7 expansion and survival can also be observed by an increase in IFN-y production by a population of CD4+ T cells (or by a population of TH1 7 cells). Thus, in an embodiment, the antagonist of the present invention inhibits IFN-y production by a population of CD4+ T cells. At a molecular level, the antagonist of IL-7 receptor mediated TH1 7 expansion and/or survival may inhibit IL-7 15 receptor mediated STAT-5 phosphorylation. Thus, in another aspect, the invention provides a method for the treatment of an autoimmune disease or inflammatory disorder, comprising administering to a patient a antagonist of IL-7 or CD127 in an amount sufficient to reduce the TH1 7 cell count in the patient. 20 In another aspect, the invention provides a method for the treatment of an autoimmune disease in a human subject, comprising administering to the subject an antagonist of IL-7 receptor mediated STAT-5 phosphorylation. In another aspect, the present invention provides a method for treating multiple sclerosis in a patient comprising administering an antagonist of IL-7 or CD127 to said 25 patient, wherein the patient is suffering from relapsing remitting multiple sclerosis. In another aspect, the invention provides a method of treating an autoimmune or inflammatory disease in a human subject, comprising administering to the subject an antagonist of IL-7 or IL-7R in an amount effective to reduce the ratio of TH1 7 cells relative to TH cells. 30 In another aspect, the invention provides a method of treating an autoimmune or inflammatory disease in a human subject, comprising administering to the subject an antagonist of IL-7 or IL-7R in an amount effective to reduce the ratio of TH cells relative to (Foxp3+) Treg cells. In an embodiment of the above methods, the antagonist is selected from the 35 group consisting of (a) a binding protein which specifically binds to CD127 (SEQ ID NO:1); 5 WO 2010/017468 PCT/US2009/053136 (b) a binding protein which specifically binds to IL-7, (c) a soluble CD127 polypeptide; and (d) a combination of two or more of said antagonists. In an embodiment, the binding protein which specifically binds CD127 or IL-7 is an isolated human, humanized or chimeric antibody. In an embodiment, the binding protein 5 which specifically binds to CD127 (an anti-CD127 binding protein) is an antibody, or an antigen-binding fragment thereof. In some embodiments, the anti-CD127 binding protein inhibits the binding of IL-7 to the IL-7R receptor complex. Certain anti-CD127 antibodies useful in the methods of the present invention are described herein, and include 9B7, 6C5, 6A3, R34.34, GR34 and 1A11, humanised or 10 chimeric versions thereof, analogs thereof, and antigen-binding fragments thereof. In an embodiment, the binding protein which specifically binds to IL-7 (an anti-IL-7 binding protein) is an antibody, or an antigen-binding fragment thereof. In another aspect, the invention provides a chimeric, humanised or fully human antibody or an antigen-binding fragment thereof which binds to CD127 and which is 15 capable of inhibition of IL-7 mediated TH1 7 expansion. The present inventors have determined that anti-CD127 binding proteins are not uniformly effective at functionally neutralising the IL-7 pathway or IL-7R mediated signalling. On the contrary, there are certain regions of the human CD127 polypeptide which appear to play an important role in the signalling pathway, to the extent that an 20 antibody which is capable of binding to one or more of these regions of human CD127 is particularly effective in neutralising the IL-7 pathway or IL-7R mediated signalling. These regions are defined by amino acid residues: (i) 41 SCYSQLEVNGSQHSLTCAFEDPD 63 (SEQ ID NO:1 17), (ii) 65 NTTNLEFEICGALVEV 80 (SEQ ID NO:118), 25 (iii) 84 NFRKLQEIYFIETKKFLLIGKS 105 (SEQ ID NO:119), (iv) 148 VTFNTSHLQKKYVKVLMHDVAY 169 (SEQ ID NO:120), and (v) 202 EIKVRSIPDHYFKGFWSE 219 (SEQ ID NO:121) of SEQ ID NO:1. It is postulated that these regions contain amino acids which play a role in the interaction between the ligand IL-7 and the CD127 receptor. The following amino acids 30 are believed to be of particular significance in the IL-7/CD127 interaction: amino acids (a) 51 SQH 53 (SEQ ID NO:122), (b) 77 LVE 79 (SEQ ID NO:123), (c) 97 KKFLLIG 103 (SEQ ID NO:124), (d) 158 KY 159 (SEQ ID NO:125), and 35 (e) 212 YF 213 (SEQ ID NO:126). 6 WO 2010/017468 PCT/US2009/053136 Binding more than one of these regions may be of significance in the inhibition of IL-7R function. In an embodiment, the antigen-binding proteins are capable of binding to at least one amino acid within, or an amino acid flanking or structurally neighbouring, at least one 5 or a plurality of regions (i) to (iv) as defined above. In another embodiment, the antigen binding proteins are capable of binding to at least one amino acid within, or an amino acid, at least one of the regions (a) to (e), as defined above. In an embodiment, the invention provides antigen-binding proteins which are capable of binding to at least one amino acid within a region defined by amino acid 10 residues 202 to 219 of SEQ ID NO:1. The antigen-binding protein according to this embodiment may further be capable of binding to at least one amino acid within one, two, three or all four of the regions defined by amino acid residues (i) 41 to 63, (ii) 65 to 80, (iii) 84 to 105 and (iv) 148 to 169 of SEQ ID NO:1. In an embodiment, the antigen-binding protein binds to at least one amino acid 15 within a region defined by amino acids (v) 202 to 219 of SEQ ID NO:1 and at least one amino acid within a region defined by amino acids (iv) 148 to 169 of SEQ ID NO:1. The antigen-binding protein according to this embodiment may further be capable of binding to at least one amino acid within a region defined by amino acids (ii) 65 to 80 and/or (iii) 84 to 105 of SEQ ID NO:1. In a particular embodiment, the antigen-binding protein binds 20 to at least one amino acid within each of peptides (ii) 65 to 80, (iii) 84 to 105, (iv) 148 to 169, and (v) 202 to 219 of SEQ ID NO:1. In another embodiment, the invention provides antigen-binding proteins which are capable of binding to at least one amino acid within a region defined by amino acid residues (e) 212 to 213 of SEQ ID NO:1, or a flanking or structurally neighbouring amino 25 acid. The antigen-binding protein according to this embodiment may further be capable of binding to at least one amino acid within, flanking or structurally neighbouring to, one, two, three or all four of the regions defined by amino acid residues (a) 51 to 53, (b) 77 to 79, (c) 97 to 103 and (d) 158 to 159 of SEQ ID NO:1. In an embodiment, the binding protein binds to at least one amino acid within a 30 region defined by amino acids (e) 212 to 213 of SEQ ID NO:1, or a flanking or structurally neighbouring amino acid, and at least one amino acid within, flanking, or structurally neighbouring to a region defined by amino acids (d) 158 to 159 of SEQ ID NO:1. The binding protein according to this embodiment may further be capable of binding to at least one amino acid within, flanking or structurally neighbouring to a region defined by amino 35 acids (b) 77 to 79 and/or (c) 97 to 103 of SEQ ID NO:1. In a particular embodiment, the 7 WO 2010/017468 PCT/US2009/053136 binding protein binds to at least one amino acid within each of peptides (b) 77 to 79, (c) 97 to 103, (d) 158 to 159, and (e) 212 to 213 of SEQ ID NO:1. Antibodies according to these aspects of the invention include 6A3, 1A11, 6C5 and 9B7, antigen-binding fragments thereof and chimeric or humanised variants thereof. 5 Additional antibodies of these aspects of the invention are chimeric or humanised variants of R3434 or GR34, or an antigen-binding fragment of R3434 or GR34. In another aspect, the invention provides a human, humanised or chimeric antibody, or a fragment thereof, wherein the antibody or fragment binds to an epitope of human CD127 that contains at least one amino acid residue within the region beginning 10 at residue number 80 and ending at residue number 190. In an embodiment, the invention provides an antibody or fragment thereof which binds to an epitope of human CD127 (SEQ ID NO:1), wherein said epitope has an amino acid residues which are present in at least one of the regions of CD127 of SEQ ID NOs:20-28, 45-50,67-70, 87-89, and 106-116. This binding may be measured by, inter 15 alia, peptide ELISA, surface plasmon resonance (BlAcore) or phage display. In particular embodiments, the antibody or fragment thereof binds to an epitope of human CD127 (SEQ ID NO:1), wherein said epitope has amino acid residues which are present in: one, two, three or four of the regions of SEQ ID NOs:66-70; one, two or three of the regions of CD127 of SEQ ID NOs:87-89; or one, two or three of the regions of 20 CD127 of SEQ ID NOs:114-116. In an embodiment, the invention provides an antibody or fragment thereof which binds to an epitope of human CD127, wherein said epitope has an amino acid residue present in at least one of the following regions of CD127: 35-49 (SEQ ID NO:20), 84-105 (SEQ ID NO:21) 171-180 (SEQ ID NO:22), or an antibody or fragment which binds to an 25 at least one of the following linear peptides: 35-49 (SEQ ID NO:20), 84-105 (SEQ ID NO:21) 171-180 (SEQ ID NO:22). This binding may be measured by, inter alia, peptide ELISA, suface plasmon resonance (BlAcore), or phage display. In an embodiment, the invention provides an antibody or fragment thereof which binds to an epitope of human CD127 (SEQ ID NO:1), the epitope having an amino acid residue present within, or the 30 epitope being present within the following regions of CD127 (SEQ ID NO:1): 80-94 (SEQ ID NO:23), 95-109 (SEQ ID NO:24), 170-184 (SEQ ID NO:25). In an embodiment, the invention provides an antibody or fragment thereof which binds to an epitope of human CD127 (SEQ ID NO:1), the epitope having an amino acid residue present within, or the epitope being present within the following regions of CD127 (SEQ ID NO:1): 35-49 (SEQ 35 ID NO:26), 84-105 (SEQ ID NO:27), 139-184 (SEQ ID NO:28). 8 WO 2010/017468 PCT/US2009/053136 In another aspect of the invention, there is provided an antibody or fragment thereof which binds to a C-terminal biotinylated CD127 peptide that comprises residues 35-49, 84-105, 171-180 of CD127 as determined by surface plasmon resonance, said peptide being bound to a streptavidin sensor chip. 5 In another embodiment, the antibody or fragment thereof additionally requires at least one flanking residue or structurally neighbouring residue to said at least one residue in the 35-49, 84-105 or 171-180 regions of CD127 for binding. The person skilled in the art can readily identify such antibodies or fragments thereof using, for example, alanine replacement scanning in ELISA assays. In this 10 respect, whether or not the antibody requires a residue in the abovedefined regions of CD127, or a flanking or structurally neighbouring residue, for binding can be determined by independently substituting said residue of CD127 with alanine and comparing the binding affinity of the antibody to the alanine substituted CD127 peptide with the binding affinity of the antibody to the wild type CD127. Whether or not a residue in the 15 abovedefined regions of CD127 is required is defined by a reduction in binding affinity of the antibody to the alanine substituted CD127 compared with the wild-type CD127, wherein said reduction is more than 1, 2, 3, 4 or 5 fold as determined by Biacore or ELISA affinity measurements. Further, a structurally neighbouring residue in this context is a residue that is in 20 close proximity in three-dimensional space to the residue in question and which is bound by the antibody. The person skilled in the art appreciates that antigen epitopes may be either liner or non-liner peptide sequences. In the latter, non-linear case, although the residues are from different regions of the peptide chain, they may be in close proximity in the three dimensional structure of the antigen. Such structurally neighbouring residues 25 can be determined through computer modelling programs or via three-dimensional structures obtained through methods known in the art, such as X-ray crystallography. Another aspect of the present invention relates to therapeutic antibodies and antigen-binding fragments thereof which are specific for CD127, and which are useful in the treatment of autoimmune and/or inflammatory disorders. The antibodies and antigen 30 binding fragments may inhibit TH17 expansion and survival and/or inhibit pSTAT-5, in an assay that as that herein defined. These antibodies and antigen-binding fragments may represent the antagonist useful in the methods of the invention. More particularly, in one aspect, there is provided an antibody or antigen-binding fragment and/or derivative thereof which binds to CD127 and which comprises at least a 35 third heavy chain CDR (CDRH3) selected from the group consisting of: 9B7-CDRH3 9 WO 2010/017468 PCT/US2009/053136 (SEQ ID NO:6); 6C5-CDRH3 (SEQ ID NO:33), 6A3-CDRH3 (SEQ ID NO:55) or 1A11 CDRH3 (SEQ ID NO:75). In an embodiment, the antibody or antigen-binding fragment and/or derivative thereof comprises CDRH3 of: antibody 9B7 (SEQ ID NO:6) and one, two, three, four or all 5 five additional CDRs of 9B7 (SEQ ID NOs:4,5,7,8,9); antibody 6C5 (SEQ ID NO:33) and one, two, three, four or all five additional CDRs of 6C5 (SEQ ID NOs: 31,32,34,35,36); antibody 6A3 (SEQ ID NO:55) and one, two, three, four or all five additional CDRs of 6A3 (SEQ ID NOs: 53,54,56,57,58); or antibody 1A11 (SEQ ID NO:75) and one, two, three, four or all five additional CDRs of A1 1 (SEQ ID NOs:73,74,76,77,78). 10 In another aspect there is provided a therapeutic antibody which is an antibody or an antigen binding fragment and/or derivative thereof which binds to CD127 and which comprises the following CDRs, or analogs thereof: A: CDRH1: RYNVH (SEQ ID NO:4); 15 CDRH2: MIWDGGSTDYNSALKS (SEQ ID NO:5); CDRH3: NRYESG (SEQ ID NO:6); CDRL1: KSSQSLLNSGNRKNYLT (SEQ ID NO:7); CDRL2: WASTRES (SEQ ID NO:8); and CDRL3: QNDYTYPFTFGS (SEQ ID NO:9). 20 B: CRDH1: AYWMS (SEQ ID NO:31) CDRH2: EINPDSSTINCTPSLKD (SEQ ID NO:32) CDRH3: RLRPFWYFDVW (SEQ ID NO:33) CDRL1: RSSQSIVQSNGNTYLE (SEQ ID NO:34) 25 CDRL2: KVSNRFS (SEQ ID NO:35) CDRL3: FQGSHVPRT (SEQ ID NO:36) C: CRDH1: TDYAWN (SEQ ID NO:53) CDRH2: YIFYSGSTTYTPSLKS (SEQ ID NO:54) 30 CDRH3: GGYDVNYF (SEQ ID NO:55) CDRL1: LASQTIGAWLA (SEQ ID NO:56) CDRL2: AATRLAD (SEQ ID NO:57) CDRL3: QQFFSTPWT (SEQ ID NO:58) 35 D: CDRH1: GYTMN (SEQ ID NO:73) CDRH2: LINPYNGVTSYNQKFK (SEQ ID NO:74) 10 WO 2010/017468 PCT/US2009/053136 CDRH3: GDGNYWYF (SEQ ID NO:75) CDRL1: SASSSVTYMHW (SEQ ID NO:76) CDRL2: EISKLAS (SEQ ID NO:77) CDRL3: QEWNYPYTF (SEQ ID NO:78). 5 In another aspect there is provided a therapeutic antibody which is a human, humanised or chimeric antibody or an antigen binding fragment and/or derivative thereof which binds to CD127 and which comprises the following CDRs, or analogs thereof: 10 CDRH1: GYTMN (SEQ ID NO:92) CDRH2: LINPYSGITSYNQNFK (SEQ ID NO:93) CDRH3: GDGNYWYF (SEQ ID NO:94) CDRL1: SASSSVSYMHW (SEQ ID NO:95) CDRL2: EISKLAS (SEQ ID NO:96) 15 CDRL3: QYWNYPYTF (SEQ ID NO:97). Throughout this specification, the terms "CDR", "CDRL1 ", "CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" follow the Kabat numbering system, as set forth in Kabat et al; Sequences of proteins of Immunological Interest NIH, 1987. Therefore the following 20 defines the CDRs according to the invention: CDR Residues CDRH1 31-35, 35(A), 35(B) CDRH2 50-65 25 CDRH3 95-97 CDRL1 24-34 CDRL2 50-56 CDRL3 80-97 30 In another aspect, there is provided a monoclonal antibody comprising: (i) the heavy chain variable region of SEQ ID NO:2 and/or the light chain variable region of SEQ ID NO:3; (ii) the heavy chain variable region of SEQ ID NO:29 and/or the light chain variable region of SEQ ID NO:30; 35 (iii) the heavy chain variable region of SEQ ID NO:51 and/or the light chain variable region of SEQ ID NO:52; or 11 WO 2010/017468 PCT/US2009/053136 (iv) the heavy chain variable region of SEQ ID NO:71 and/or the light chain variable region of SEQ ID NO:72. Also provided by the present invention are antibody variable domain sequences that have at least 90% identity, or at least 95% identity, or at least 98% identity, or at least 5 99% identity, over the whole length of the sequences of SEQ ID NOs: 2, 3, 29, 30, 51, 52, 71, and 72. Also provided by the invention is a method of treatment of an autoimmune disease or inflammatory disorder comprising administering to a patient an anti-CD127 antibody, wherein the antibody comprises: 10 (i) the heavy chain variable region of SEQ ID NO:2 and/or the light chain variable region of SEQ ID NO:3; (ii) the heavy chain variable region of SEQ ID NO:29 and/or the light chain variable region of SEQ ID NO:30; (iii) the heavy chain variable region of SEQ ID NO:51 and/or the light 15 chain variable region of SEQ ID NO:52; (iv) the heavy chain variable region of SEQ ID NO:71 and/or the light chain variable region of SEQ ID NO:72; or (v) the heavy chain variable region of SEQ ID NO:90 and/or the light chain variable region of SEQ ID NO:91, 20 or a monoclonal antibody having a heavy and light chain variable regions that have at least 90% identity, or at least 95% identity, or at least 98% identity, or at least 99% identity, to these heavy and/or light chain variable regions. In another aspect, the invention provides an antibody or an antigen-binding fragment thereof which binds to CD127 and which is capable of inhibition of IL-7 25 mediated TH1 7 expansion, wherein the antibody is not R.34.34 (Dendritics Inc.,#DDX0700). In another aspect of the present invention, there is provided a method for identifying antibodies or antibody fragment suitable for use in the treatment of an autoimmune disease or an inflammatory disease, the method comprising the steps of: 30 screening a plurality of independent antibody or antibody fragment populations to determine the ability of each antibody population to: i. inhibit the binding of IL-7 to IL-7R, ii. neutralise IL-7 induced STAT-5 phosphorylation, and/or iii. inhibit the production of IL-17 by TH1 7 cells, 12 WO 2010/017468 PCT/US2009/053136 and selecting those antibody or antibody fragment populations which are able to inhibit the binding of IL-7 to IL-7R, inhibit IL-7 induced STAT-5 phosphorylation, and/or inhibit the production of IL-17 by TH1 7 cells in vivo. The ability of a composition or substance (a test agent) to act as an antagonist of 5 IL-7 receptor mediated TH1 7 expansion or IL-7 receptor mediated TH1 7 survival, or to reduce TH1 7 cell count, can be determined by routine methods. For example, naive CD4' cells can be stimulated to differentiate into TH1 7 with appropriate conditions known to those of skill in the art (e.g. TGF-p1, IL-23, IL-6, anti-IFN-y and anti-IL-4, or IL-1p, IL-6 and IL-23). A TH1 7 population of cells can then be exposed to the test agent and IL-7, 10 following which the TH1 7 cell count can be determined. A decrease in TH1 7 cells relative to a control would indicate that the test agent is capable of inhibiting TH1 7 expansion or survival. In another aspect of the invention, there is provided a method of manufacturing a medicament for the treatment of autoimmune or inflammatory disease, the method 15 comprising formulating an anti-CD127 or anti-IL-7 antibody or antigen-binding fragment thereof and one or more excipients into a pharmaceutically acceptable formulation. This method may comprise the preliminary steps of identifying an antibody, as hereinbefore defined, and/or of recombinantly producing such an antibody. In the definitions of the epitopes of CD127 that are bound by the binding proteins 20 and antibodies of the present invention, the numbering system used refers to the full length sequence of CD127, which includes the signal sequence. In one embodiment the epitopes of human CD127 are found within the cited residues of SEQ ID NO:1. In one embodiment, the binding proteins of the present invention binds to human CD127 with an affinity (KD) which is less than 20nM, less than 15nM, less than 10nM, 25 less than 5nM, less than 1nM or less than 0.5nM, as measured by surface plasmon resonance (BlAcore) . In an embodiment, the binding protein competitively inhibits binding of 9B7, 6C5, 3A6, A1 1 or R34.34 (Dendritics Inc. #DDX0700), or an antigen-binding fragment thereof to human CD127. 30 Competitive inhibition can be determined by those skilled in the art, for example, in a competition ELISA assay, by BlAcore or Scatchard analysis. In one aspect of the present invention, there are provided isolated binding proteins which compete with: i. antibody R34.34 (Dendritics Inc.,#DDX0700); 35 ii. an antibody having a variable heavy chain region as set out in SEQ ID NO:2 and a variable light chain region as set out in SEQ ID NO:3; 13 WO 2010/017468 PCT/US2009/053136 iii. an antibody having a variable heavy chain region as set out in SEQ ID NO:29 and a variable light chain region as set out in SEQ ID NO:30; iv. an antibody having a variable heavy chain region as set out in SEQ ID NO:51 and a variable light chain region as set out in SEQ ID NO:52; 5 v. an antibody having a variable heavy chain region as set out in SEQ ID NO:71 and a variable light chain region as set out in SEQ ID NO:72; or vi. an antibody having a variable heavy chain region as set out in SEQ ID NO:90 and a variable light chain region as set out in SEQ ID NO:91, for binding to CD127, wherein the antibody is not R.34.34 (Dendritics Inc.,#DDX0700). 10 In a particular embodiment, the isolated binding protein of the present invention is an antibody or an antigen-binding fragment thereof which competes with: i. antibody R34.34 (Dendritics Inc.,#DDX0700); ii. an antibody having a variable heavy chain region as set out in SEQ ID NO:51 and a variable light chain region as set out in SEQ ID NO:52; 15 iii. an antibody having a variable heavy chain region as set out in SEQ ID NO:71 and a variable light chain region as set out in SEQ ID NO:72; or iv. an antibody having a variable heavy chain region as set out in SEQ ID NO:90 and a variable light chain region as set out in SEQ ID NO:91, for binding to CD127, wherein the antibody is not R.34.34 (Dendritics Inc.,#DDX0700). 20 Also provided by the present invention are binding proteins for use in the treatment of multiple sclerosis, wherein the binding proteins compete for binding to human CD127 (SEQ ID NO:1) with: i. antibody R34.34 (Dendritics Inc.,#DDX0700); ii. an antibody having a variable heavy chain region as set out in SEQ ID 25 NO:2 and a variable light chain region as set out in SEQ ID NO:3; iii. an antibody having a variable heavy chain region as set out in SEQ ID NO:29 and a variable light chain region as set out in SEQ ID NO:30; iv. an antibody having a variable heavy chain region as set out in SEQ ID NO:51 and a variable light chain region as set out in SEQ ID NO:52; 30 v. an antibody having a variable heavy chain region as set out in SEQ ID NO:71 and a variable light chain region as set out in SEQ ID NO:72; or vi. an antibody having a variable heavy chain region as set out in SEQ ID NO:90 and a variable light chain region as set out in SEQ ID NO:91, for binding to CD127. 35 The person skilled in the art appreciates that in order for an antibody or fragment (antibody or fragment A) to compete with antibody R34.34, GR34, 6A3, A1 1, 6C5 or 9B7 14 WO 2010/017468 PCT/US2009/053136 (antibody B) for a specific binding site (of human CD127), antibody A must be present in a sufficient amount to have an effect in said assay. For example, antibody A and antibody B may be present in equimolar amounts. If antibody A is a competing antibody, the presence of antibody A may reduce the binding of antibody B to human CD127 in an 5 ELISA assay by more than 10%, 20%, 30%, 40% or 50%. A competing antibody (antibody A) may reduce the binding of antibody B to plate-bound human CD127, whereas a non-anti-CD127-specific control does not. In such ELISA assays human CD127 may be bound to an immunoassay plate. In another assay system, surface plasmon resonance may be used to determine competition between antibodies. 10 Isolated binding proteins which are capable of competition for binding to CD127 with antibody R34.34 or the antibodies of the invention, an isolated binding protein having a VH of SEQ ID NO:2 and VL of SEQ ID NO:3, an isolated binding protein having a VH of SEQ ID NO:76 and a VL of SEQ ID NO:77, or an isolated binding protein having a VH of SEQ ID NO:193 and a VL of SEQ ID NO:194 may be used in the treatment of MS and 15 other autoimmune diseases. The binding proteins of the present invention may comprise the CDRs of R34.34, GR34, 9B7, 6A3, A1 1 or 6C5, or they may comprise analogs thereof. Also provided by the present invention are humanized antibodies, wherein the R34.34, GR34, 9B7, 6A3, 1A11 or 6C5 CDRs (or analogs thereof) are grafted into a 20 heavy chain or light chain variable domain framework. In another aspect of the present invention there is provided a polynucleotide sequence which encodes the binding proteins of the present invention. In particular, there is provided a polynucleotide sequence that encodes an antibody or fragment thereof which comprises one or all of the CDRs found in 9B7 (SEQ ID NOs:4-9), 6C5 (SEQ ID NOs:31 25 36), 6A5 (SEQ ID NOs:53-58), 1A11 (SEQ ID NOs:73-78) or GR34 (SEQ ID NOs:92-97). In a related aspect of the present invention there is provided a host cell transfected with the polynucleotides of the present invention. The binding proteins, antibodies, antigen-binding fragments, their humanised, human or chimeric variants, and analogs, of the present invention may be used in a 30 method of treatment of multiple sclerosis, the method comprising administering a safe and effective dose of the binding proteins of the present invention to a patient in need thereof. In this aspect of the present invention the binding protein may be an antibody which comprises one or all of the CDRs found in 9B7 (SEQ ID NOs:4-9), 6C5 (SEQ ID NOs:31-36), 6A5 (SEQ ID NOs:53-58), 1A11 (SEQ ID NOs:73-78) or GR34 (SEQ ID 35 NOs:92-97). 15 WO 2010/017468 PCT/US2009/053136 Also provided in this aspect of the present invention is a method where the patient in need of the treatment is a relapsing/remitting MS (RRMS) patient who is about to, or is in, a relapse phase. In another aspect, the invention provides a method of treating an autoimmune or 5 inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of an antagonist of IL-7 or IL-7R and an additional therapeutic agent. The additional therapeutic agent may be selected from the group consisting of: immunomodulators such as interferon beta (IFNp-la or IFNp-1b) and glatiramer acetate, 10 immunosuppresants such as cyclophosphamide, methotrexate, azathioprine, cladribine, cyclosporine and mitoxantrone, other immune therapies such as intravenous immune globulin (IVlg), plasma replacement and sulphasalazine. The additional therapeutic may be administered as in a manner (dosage, timing, mechanism) as prescribed by a physician. In an embodiment, the additional therapeutic agent may be administered 15 simultaneously or sequentially or separately from the antagonist of the present invention. In an embodiment, the additional therapeutic agent and the antagonist are administered such that their pharmacological effects on the patient overlap; in other words, they exert their biological effects on the patient at the same time. In another embodiment of the invention, the IL7/IL7R antagonist is a soluble 20 CD127 polypeptide. The soluble CD127 polypeptide may comprise a polypeptide which is 90% or more identical to a polypeptide selected from the extracellular domain of CD127 (SEQ ID NO:1), or a polypeptide comprised of amino acids 21 to 219 of SEQ ID NO:1. In certain embodiments, the soluble CD127 comprises a polypeptide is amino acids 21-219 of SEQ ID NO:1. In further embodiments, the soluble CD127 polypeptide may be fused 25 to a non-CD127 moiety. The non-CD127 moiety may be a heterologous peptide fused to the soluble CD127 polypeptide. In an embodiment, the non-CD127 moiety is selected from the group consisting of serum albumin, a targeting protein, an immunoglobulin fragment, a reporter protein or a purification-facilitating protein. In a particular embodiment, the soluble CD127 polypeptide is fused to an Fc region of an 30 immunoglobulin. Brief Description of the Figures Figure 1(A) shows inhibition of IL-7-mediated pSTAT5 by anti-mouse CD127 antibodies; Figure 1(B) shows inhibition of TSLP mediated pSTAT5 by anti-mouse CD127 antibodies; 35 Figure 2 shows a CD127 ELISA binding curve for 9B7; 16 WO 2010/017468 PCT/US2009/053136 Figure 3 (A) shows that MAb 9B7 (solid line) is capable of recognizing CD127 expressed on the surface of CD127-transfected CHO cell line. An irrelevant, isotype control, antibody is shown as a dotted line; Figure 3(B) shows that antibody 9B7 (solid line) is not capable of recognizing CD127 in a 5 mock transfected CHO cell line - an irrelevant, isotype control, antibody is shown as a dotted line; Figure 4 demonstrates an example of the inhibition of 1L7-mediated pStat5 signalling by purified murine anti-CD127 mAb 9B7; Figure 5(A) shows that the MOG-EAE clinical score was ameliorated by rat anti-murine 10 CD127 antibody SB/14; Figure 5(B) shows inhibition of MOG peptide-induced T-cell proliferation by SB/14; Figure 5(C) shows inhibition of cytokine production by anti-CD127 antibody by SB/14; Figures 5(D) and 5(E) show the selective effect of anti-mCD127 antibody (SB/14) treatment on helper T cell subtypes; 15 Figure 5(F) shows that the MOG-EAE clinical score was ameliorated by anti-mCD127 antibody (SB/14) treatment; Figure 6 shows CD127 expression in Treg, TH1 and TH1 7 cells derived ex vivo from spleen or spinal cord of EAE mice; Figure 7(A) shows that the effect of IL-7 on the promotion of TH17 differentiation was 20 modest compared to that of IL-6; Figure 7(B) shows that the induction of STAT-3 phosphorylation is largely driven by IL-6 independently from IL-7; Figure 7(C) shows that the effect of IL-7 on RORa expression is also modest compared to that of IL-6; 25 Figure 7(D) shows that the effect of anti-mCD127 antibody (SB/14) treatment was modest during disease onset in EAE; Figure 8(A) shows the percentage of TH1 7 cells, y-interferon secreting TH1 cells, and Treg cells in the CNS; Figure 8(B) shows the percentage of TH1 7 cells, y-interferon secreting TH1 cells, and Treg 30 cells in splenocytes; Figure 8 (C) shows the percentage of TH1 7 , TH1 and Treg in the course of EAE in both treated and control mice; Figure 9(A) shows the effect of an anti-CD127 antibody (SB/14) of TH1 7 and TH cell counts, but not Treg count, was inhibited when CD127 antibody was added in the onset of 35 differentiation; 17 WO 2010/017468 PCT/US2009/053136 Figure 9(B) shows the effect of an anti-mCD127 antibody (SB/14) as in Figure 9(A), but on differentiated TH1 7 , but not TH1 or Treg; Figure 10 shows that addition of IL-7 promoted TH1 7 expansion/survival and, to a lesser degree, TH1, but not Foxp3 in Treg, when day 9 EAE MOG-specific T cells were cultured; 5 Figure 11(A) shows an immunoblot analysis of CD4+ T cells derived ex vivo from treated or control EAE mice showing anti-CD127 antibody treatment changes in signaling pathways related to JAK-STAT and apoptosis as characterized by down-regulation of phosphorylated JAK-1 and phosphorylated STAT-5 and markedly decreased levels of a key pro-apoptotic molecule, BCL-2, and increased activity of an anti-apoptotic molecule, 10 BAX; Figure 11(B) shows that anti-CD127 antibody treatment increased the percentage of Annexin-V+ apoptotic cells among CD4+CD127+ T cells compared to that of CD4+CD127- T cells derived from treated EAE mice; Figure 11(C) shows that differentiated TH1 7 cells derived from EAE mice undergo 15 apoptosis which can be rescued with IL-7, but this process is slowed if the cells are pre incubated with an anti-CD127 antibody; Figure 11(D) shows that the effects of IL-7 are mediated through the JAK/STAT-5 pathway; Figure 12 shows mAb 9B7 and R34.34 have minimal inhibitory effect on the differentiation 20 of TH1 7 from human total CD4+ cells. Figure 13 shows mAb 6C5 inhibition of CD127-ECD binding to immobilised IL-7; Figure 14 shows that mAb 6C5 competes with IL-7 for binding to CD127; Figure 15 shows that mAb 6C5 and Dendritics antibody R.34.34 compete for binding to CD127; 25 Figure 16(A) shows mAb 6A3 inhibition of CD127-ECD binding to immobilised IL-7; Figure 16(B) is an inhibition ratio curve of antibodies 6A3, 6C5 and R34.34 at different concentrations of antibody, showing the effect of these antibodies on the binding of CD127-ECD to IL-7; Figure 17 shows that mAb 6A3 competes with IL-7 for binding to CD127 expressed on 30 CHO cells; Figure 18 shows mAb 6C5 and antibody R.34.34 both inhibit the production of IFNy by IL 7 stimulated PBMCs; Figure 19 shows the ability of antibodies BD, R34.34, 1A11 and 6C5 to block Stat5 signalling induced by IL-7 stimulated PBMCs; 35 Figure 20 shows the ability of antibodies BD, R34.34, 1A11 and 6C5 to block Stat5 signalling induced by IL-7 stimulated CCF-CEM cells; 18 WO 2010/017468 PCT/US2009/053136 Figure 21 shows the ability of mAb 6A3 to inhibit IL-17 and IFN-y production in a TH17 expansion assay; Figure 22 shows the inhibitory effect of various anti-CD127 antibodies on the production of IL-17 by hCD4' cells under IL-7 stimulation; 5 Figure 23 shows the inhibitory effect of mAb 6A3 on IFN-y production and IL-17 production by TH1 7 cells. Detailed description of the invention The invention is based on the discovery that IL-7/IL-7R signalling is critically 10 required for survival and expansion of committed TH1 7 cells in both mouse and human systems, while its role in TH1 7 differentiation is not essential compared to that of IL-6. Surprisingly, the in vivo effect on the immune system by IL-7R antagonism is highly selective in EAE, an animal model for multiple sclerosis, affects TH1 7 cells and, to a lesser extent, TH1 cells predominantly of the memory phenotype, and spares Treg cells. 15 This selectivity appears to play an important role in rebalancing the ratio of pathogenic TH1 7 cells and Treg cells by IL-7R antagonism in EAE and is attributable to the treatment efficacy. The novel mechanism of action of IL-7/IL-7R signalling in TH1 7 cell survival and expansion as discussed above provides a powerful explanation for the treatment efficacy of IL-7R antagonism in EAE and therapeutic implications for human autoimmune 20 diseases, such as MS. IL-7 neutralization or IL-7R antagonism is likely to have unique therapeutic advantages. On one hand, the treatment offers the selectivity that distinguishes pathogenic TH1 and TH1 7 cells from Treg and unrelated immune cells. On the other hand, additional therapeutic advantages of IL-7R antagonism involve its selective effect on survival and expansion of differentiated TH1 7 as opposed to TH1 7 differentiation. 25 It is conceivable that targeting in vivo maintenance of committed TH1 7 versus TH17 differentiation is more efficacious in a therapeutic context. Inhibition of IL-7 receptor mediated signalling therefore provides a promising therapeutic intervention for the treatment of autoimmune or inflammatory diseases. The term IL-7R mediated signalling, as used herein, means the biological effect 30 instigated by the IL-7 receptor complex when bound by its ligand, IL-7. IL-7R mediated signalling therefore includes, but is not necessarily limited to, one or more, or all, of IL-7 induced phosphorylation of STAT-5, IL-7 induced expansion of TH1 7 cells and IL-7 induced survival of TH1 7 cells. 35 Antagonists 19 WO 2010/017468 PCT/US2009/053136 An IL-7 pathway antagonist as used herein is any entity that functionally blocks the biological effects of IL-7, measurable by assays. At the molecular level, one can observe and measure the blocking effect by assays such as IL-7-induced P-STAT5 or Bcl-2. Exemplary p-STAT5 assays are described herein. At the cellular level, one can 5 observe and measure the blocking effect by assays such as Th17 secretion of IL-17 or IFNy. Exemplary assays are also described herein. The IL-7/IL-7R pathway antagonists useful in the present invention are capable of inhibiting, partially or in full, phosphorylation of STAT-5 induced by IL-7. STAT-5 phosphorylation can be determined by methods routine in the art, for instance, in an 10 assay such as that described herein (Example 2.3). In such an assay, PBMCs are stimulated with IL-7 in the presence and absence of a test agent. Cells are subsequently assessed quantitatively for the level of pSTAT-5, e.g. by staining for pSTAT-5 (e.g. with a labelled anti-pSTAT-5 antibody) followed by fluorescence activated cell sorting. The levels of phosphorylated STAT-5 could also be determined by ELISA. Those agents 15 which reduce the level of phosphorylated STAT-5 may be potential therapeutic candidates for autoimmune disease. The antagonist may be capable of reducing levels of phosphorylated STAT-5 by at least 20%, 50%, 75%, 80%, 85%, 90%, 95% or 100% when compared to STAT-5 levels in the absence of the antagonist, or when compared to a negative control, or untreated 20 cells. The antagonist may have an IC50 of 50pg/ml, 25pg/ml or less, 10pg/ml or less, 5pg/ml or less, or 2pg/ml or less. In an embodiment, the antagonist has an IC50 of less than or equal to 1pg/ml, less than or equal to 0.75pg/ml, less than or equal to 0.5pg/ml, less than or equal to 0.25pg/ml, or less than or equal to 0.1 pg/ml. The antagonists of the invention are particularly effective in inhibiting the 25 expansion of TH1 7 cells. Expansion of TH1 7 cells can be determined in a TH1 7 expansion assay, which comprises stimulating a population of naive T cells to expand in the presence and absence of a test agent, followed by stimulating the cells to produce IL-17 and assessing the level of IL-17 produced by the cells in the presence and absence of the test agent. 30 In an embodiment, the antagonist is capable of from 20% or more inhibition of IL 17 secretion in such an assay, versus a negative control. More typically, the antagonist is capable of from 50%, from 75%, from 85% or from 90% or more inhibition of IL-17 secretion versus the control. The antagonist may, in some embodiments, exhibit an IC50 of less than or equal to 50pg/ml in the assay. In other embodiments, the IC50 may be less 35 than or equal to 20pg/ml, 10pg/ml or 5pg/ml. 20 WO 2010/017468 PCT/US2009/053136 In an embodiment of this assay, human CD4+ T cells are differentiated into TH17 by stimulation with T cell receptor activation in the presence of IL-1, IL-6, and IL-23. After 5 days of differentiation, CCR6+ cells are sorted out to produce an enriched TH17 population. This population is then stimulated with human IL-7 and the increase in IL-17 5 and IFN-y in the supernatant are determined. Blocking the interaction between the IL-7 and CD127 by a functional IL-7/lL-7R pathway antagonist (e.g. an anti-CD127 antibody) in the incubation period should prevent the expansion of the TH1 7 cells leading to the reduction of IL-17 and IFN-y production. In this embodiment, CD4+ T cells may be isolated from human peripheral blood 10 mononuclear cells using a commercial kit (e.g. CD4+ T Cell Isolation Kit II, # 130-091 155, Miltenyi Biotec). CD4+ T cells are then typically re-suspended in RPMI medium with 10% FCS at a concentration of 1.5x1OE6/ml. Cells are pre-incubated with control or anti IL-7Ry antibodies, typically for 30 min. Cells were then cultured with or without 10 ng/ml of IL-7 for 72 h at 37 C. At the end of the incubation, cells are stimulated with 50ng/ml 15 PMA and 1ug/ml of lonomycin for 5 h. Cell culture supernatants were then collected and the IL-17 concentration is determined by ELISA (eBiosciences). Binding Protein The isolated binding proteins of the present invention may be in the form of an 20 antibody or immunoglobulin, such as an intact antibody, a human, humanized or chimeric antibody, or fragments or domains of said antibodies. These antibodies of the present invention may comprise one or more, or all of the CDRs found in 9B7 (SEQ ID NOs:4-9), 6C5 (SEQ ID NOs:31-36), 6A5 (SEQ ID NOs:53-58), 1Al 1 (SEQ ID NOs:73-78) or GR34 (SEQ ID NOs:92-97). 25 By "binding" in this context it is essentially meant that the binding protein, such as an antibody, binds to (an epitope of) CD127 via an antigen binding domain, and that the binding entails some complementarity between the antigen binding domain and (the epitope of) CD127. A binding protein therefore binds to CD127 or an epitope of CD127 more readily than it would bind to a random, unrelated polypeptide, or a random, 30 unrelated epitope. In other words, there is specificity between the binding protein and (the epitope of) CD127. The binding proteins of the invention may also be in the form of a soluble CD127 polypeptide. The binding proteins of the present invention may bind to CD127, such as a 35 monoclonal antibody that specifically binds to CD127. The binding proteins may also be entities that reduce binding of TSLP to the TSLP receptor, and also reduces binding of IL 21 WO 2010/017468 PCT/US2009/053136 7 to the IL-7 receptor, for the treatment of multiple sclerosis, such as a bispecific binding protein that binds to the IL-7 and TSLP ligands, or elements of the IL-7R and TSLPR that would give this effect, or combinations of ligands and receptors. In this regard, TSLP antagonists are described in, for example, US7304144 and W02007096149, and as 5 noted supra, the TSLP receptor comprises CD127. The antagonists of the present invention may therefore be useful as antagonists of TSLP. Isolated The term, "isolated", as it is used herein, means that the binding proteins are 10 removed from the environment in which they may be found in nature, for example, they may be purified away from substances with which they would normally exist in nature. These binding proteins may be substantially pure, in that the mass of protein in a sample would by constituted of at least 50% or at least 80% binding protein. 15 Competition A binding protein is said to competitively inhibit the binding of a reference binding protein to CD127, to a fragment of CD127 or to an epitope within CD127 if it preferentially binds to that epitope, to the extent that it blocks, to some degree, binding of the reference binding protein to CD127, or to that fragment of CD127 or epitope within CD127. 20 Competitive inhibition may be determined by any method known in the art, for example, competition ELISA assays, surface plasmon resonance (BlAcore), or Scatchard analysis. A binding protein may be said to competitively inhibit the binding of a reference binding protein to a given epitope if the binding of the reference antibody is reduced by at least 90%, at least 80%, at least 70%, at least 60% or at least 50%. 25 Intact Antibodies The binding proteins of the present invention may be "intact antibodies". Intact antibodies are usually heteromultimeric glycoproteins comprising at least two heavy and two light chains. Aside from IgM, intact antibodies are heterotetrameric glycoproteins of 30 approximately 150KDa, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond while the number of disulfide linkages between the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number 35 of constant regions. Each light chain has a variable domain (VL) and a constant region at its other end; the constant region of the light chain is aligned with the first constant region 22 WO 2010/017468 PCT/US2009/053136 of the heavy chain and the light chain variable domain is aligned with the variable domain of the heavy chain. The light chains of antibodies from most vertebrate species can be assigned to one of two types called Kappa and Lambda based on the amino acid sequence of the constant region. Depending on the amino acid sequence of the constant 5 region of their heavy chains, human antibodies can be assigned to five different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and IgAl and IgA2. Species variants exist with mouse and rat having at least IgG2a, IgG2b. The variable domain of the antibody confers binding specificity upon the antibody with certain regions displaying particular variability called 10 complementarity determining regions (CDRs). The more conserved portions of the variable region are called framework regions (FR). The variable domains of intact heavy and light chains each comprise four FR connected by three CDRs. The CDRs in each chain are held together in close proximity by the FR regions and with the CDRs from the other chain contribute to the formation of the antigen binding site of antibodies. The 15 constant regions are not directly involved in the binding of the antibody to the antigen but exhibit various effector functions such as participation in antibody dependent cell mediated cytotoxicity (ADCC), phagocytosis via binding to Fcy receptor, half life/clearance rate via neonatal Fc receptor (FcRn) and complement dependent cytotoxicity via the Clq component of the complement cascade. The human IgG2 20 constant region has been reported to essentially lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. The IgG4 constant region has been reported to lack the ability to activate complement by the classical pathway and mediates antibody-dependent cellular cytotoxicity only weakly. Antibodies essentially lacking these effector functions may be termed 'non-lytic' 25 antibodies. Human antibodies The binding proteins of the present invention may be "human antibodies". Human antibodies may be produced by a number of methods known to those of skill in the art. 30 Human antibodies can be made by the hybridoma method using human myeloma or mouse-human heteromyeloma cell lines see Kozbor J.lmmunol 133, 3001, (1984) and Brodeur, Monoclonal Antibody Production Techniques and Applications, pp51-63 (Marcel Dekker Inc, 1987). Alternative methods include the use of phage libraries or transgenic mice both of which utilize human V region repertories (see Winter G, (1994), 35 Annu.Rev.lmmunol 12,433-455, Green LL (1999), J.lmmunol.methods 231, 11-23). 23 WO 2010/017468 PCT/US2009/053136 Several strains of transgenic mice are now available wherein their mouse immunoglobulin loci has been replaced with human immunoglobulin gene segments (see Tomizuka K, (2000) PNAS 97,722-727; Fishwild D.M (1996) Nature Biotechnol. 14,845 851, Mendez MJ, 1997, Nature Genetics, 15,146-156). Upon antigen challenge such 5 mice are capable of producing a repertoire of human antibodies from which antibodies of interest can be selected. Phage display technology can be used to produce human antibodies (and fragments thereof), see McCafferty; Nature, 348, 552-553 (1990) and Griffiths AD et al (1994) EMBO 13:3245-3260. 10 Chimeric and Humanized Antibodies The binding proteins of the present invention may be "chimeric" or "humanized" antibodies. The use of intact non-human antibodies in the treatment of human diseases or disorders carries with it the now well established problems of potential immunogenicity 15 especially upon repeated administration of the antibody: that is the immune system of the patient may recognise the non-human intact antibody as non-self and mount a neutralising response. In addition to developing fully human antibodies (see above) various techniques have been developed over the years to overcome these problems and generally involve reducing the composition of non-human amino acid sequences in the 20 intact therapeutic antibody whilst retaining the relative ease in obtaining non-human antibodies from an immunised animal e.g. mouse, rat or rabbit. Broadly two approaches have been used to achieve this. The first are chimaeric antibodies, which generally comprise a non-human (e.g. rodent such as mouse) variable domain fused to a human constant region. Because the antigen-binding site of an antibody is localised within the 25 variable regions the chimaeric antibody retains its binding affinity for the antigen but acquires the effector functions of the human constant region and is therefore able to perform effector functions. Chimaeric antibodies are typically produced using recombinant DNA methods. DNA encoding the antibodies (e.g. cDNA) is isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are 30 capable of binding specifically to genes encoding the H and L chain variable regions of the antibody of the invention, e.g. DNA of SEQ ID NO:2 and 3 described supra). The DNA may be modified by substituting the coding sequence for human L and H chains for the corresponding non-human (e.g. murine) H and L constant regions see e.g. Morrison; PNAS 81, 6851 (1984). Thus in another embodiment of the invention there is provided a 35 chimaeric antibody comprising a VH domain having the sequence: SEQ ID NO:2 and a VL 24 WO 2010/017468 PCT/US2009/053136 domain having the sequence: SEQ ID NO:3 fused to a human constant region (which maybe of a IgG isotype e.g. IgG1) . The second approach involves the generation of humanised antibodies wherein the non-human content of the antibody is reduced by humanizing the variable regions. 5 Two techniques for humanisation have gained popularity. The first is humanisation by CDR grafting. CDRs build loops close to the antibody's N-terminus where they form a surface mounted in a scaffold provided by the framework regions. Antigen-binding specificity of the antibody is mainly defined by the topography and by the chemical characteristics of its CDR surface. These features are in turn determined by the 10 conformation of the individual CDRs, by the relative disposition of the CDRs, and by the nature and disposition of the side chains of the residues comprising the CDRs. A large decrease in immunogenicity can be achieved by grafting only the CDRs of a non-human (e.g. murine) antibody ("donor" antibody) onto a suitable human framework ("acceptor framework") and constant regions (see Jones et al (1986) Nature 321,522-525 and 15 Verhoeyen M et al (1988) Science 239, 1534-1536). However, CDR grafting per se may not result in the complete retention of antigen-binding properties and it is frequently found that some framework residues of the donor antibody need to be preserved (sometimes referred to as "backmutations") in the humanised molecule if significant antigen-binding affinity is to be recovered (see Queen C et al (1989) PNAS 86, 10,029-10,033, Co, M et 20 al (1991) Nature 351, 501-502). In this case, human V regions showing the greatest sequence homology (typically 60% or greater) to the non-human donor antibody maybe chosen from a database in order to provide the human framework (FR). The selection of human FRs can be made either from human consensus or individual human antibodies. Where necessary key residues from the donor antibody are substituted into the human 25 acceptor framework to preserve CDR conformations. Computer modelling of the antibody maybe used to help identify such structurally important residues, see W099/48523. Alternatively, humanisation maybe achieved by a process of "veneering". A statistical analysis of unique human and murine immunoglobulin heavy and light chain variable regions revealed that the precise patterns of exposed residues are different in 30 human and murine antibodies, and most individual surface positions have a strong preference for a small number of different residues (see Padlan E.A. et al; (1991) Mol.Immunol.28, 489-498 and Pedersen J.T. et al (1994) J.Mol.Biol. 235; 959-973). Therefore it is possible to reduce the immunogenicity of a non-human Fv by replacing exposed residues in its framework regions that differ from those usually found in human 35 antibodies. Because protein antigenicity can be correlated with surface accessibility, replacement of the surface residues may be sufficient to render the mouse variable 25 WO 2010/017468 PCT/US2009/053136 region "invisible" to the human immune system (see also Mark G.E. et al (1994) in Handbook of Experimental Pharmacology vol.113: The pharmacology of monoclonal Antibodies, Springer-Verlag, pp105-134). This procedure of humanisation is referred to as "veneering" because only the surface of the antibody is altered, the supporting 5 residues remain undisturbed. Further alternative approaches include that set out in W004/006955 and the procedure of Humaneering TM (Kalobios) which makes use of bacterial expression systems and produces antibodies that are close to human germline in sequence (Alfenito-M Advancing Protein Therapeutics January 2007, San Diego, California). 10 It will be apparent to those skilled in the art that the term "derived" is intended to define not only the source in the sense of it being the physical origin for the material but also to define material which is structurally identical to the material but which does not originate from the reference source. Thus "residues found in the donor antibody" need not necessarily have been purified from the donor antibody. 15 One aspect of the present invention is, therefore, humanized antibodies comprising one or more, or all, of the CDRs found in the mouse antibody 9B7 (SEQ ID NOs: 4-9). Multi or bispecific antibodies 20 The binding proteins of the present invention may be "multi-specific" or "bispecific" antibodies. A multispecific or bispecific antibody is an antibody derivative which prevents or reduces binding of both IL-7 and TSLP to their receptors, the antibody having binding specificities for at least two proteins selected from IL-7, TSLP, CD127, IL7R gamma chain or CRLF2, also forms part of the invention. The binding protein of the invention may also 25 have binding specificity for IL-23, which is expressed on the cell surface of TH1 7 cells, for example, the binding protein may have specificity for both IL-23R (or IL-23) and CD127, or IL-2R (or IL-23) and IL-7. Methods of making such antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the coexpression of two 30 immunoglobulin H chain-L chain pairs, where the two H chains have different binding specificities see Millstein et al, Nature 305 537-539 (1983), W093/08829 and Traunecker et al EMBO, 10, 1991, 3655-3659. Because of the random assortment of H and L chains, a potential mixture of ten different antibody structures are produced of which only one has the desired binding specificity. An alternative approach involves fusing the variable 35 domains with the desired binding specificities to heavy chain constant region comprising at least part of the hinge region, CH2 and CH3 regions. It is preferred to have the CH1 26 WO 2010/017468 PCT/US2009/053136 region containing the site necessary for light chain binding present in at least one of the fusions. DNA encoding these fusions, and if desired the L chain are inserted into separate expression vectors and are then cotransfected into a suitable host organism. It is possible though to insert the coding sequences for two or all three chains into one 5 expression vector. In one preferred approach, the bispecific antibody is composed of an H chain with a first binding specificity in one arm and an H-L chain pair, providing a second binding specificity in the other arm, see W094/04690. See also Suresh et al Methods in Enzymology 121, 210, 1986. One potential approach is to produce a bispecific antibody or bispecific fragment 10 such as described supra wherein a first specificity is towards an epitope of IL-7 and a second specificity towards TSLP. Another potential approach is a is to produce a bispecific antibody or bispecific fragment such as described supra wherein a first specificity is towards an epitope of IL-7 and a second specificity towards IL-6. 15 Antibody Fragments The binding proteins of the present invention may be "antibody fragments". In certain embodiments of the invention there is provided a therapeutic antibody which is an antigen binding fragment. Such fragments may be functional antigen binding fragments of intact and/or humanised and/or chimaeric antibodies such as Fab, Fd, Fab', F(ab') 2 , Fv, 20 ScFv fragments of the antibodies described supra. The fragments may also be human, camellid or shark or other species, single variable domain antibodies or larger constructs comprising them. Fragments lacking the constant region lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. Traditionally such fragments are produced by the proteolytic digestion of 25 intact antibodies by, e.g., papain digestion (see for example, WO 94/29348) but may be produced directly from recombinantly transformed host cells. For the production of ScFv, see Bird et al ; (1988) Science, 242, 423-426. In addition, antibody fragments may be produced using a variety of engineering techniques as described below. Fv fragments appear to have lower interaction energy of their two chains than Fab 30 fragments. To stabilise the association of the VH and VL domains, they have been linked with peptides (Bird et al, (1988) Science 242, 423-426, Huston et al, PNAS, 85, 5879 5883), disulphide bridges (Glockshuber et al, (1990) Biochemistry, 29, 1362-1367) and "knob in hole" mutations (Zhu et al (1997), Protein Sci., 6, 781-788). ScFv fragments can be produced by methods well known to those skilled in the art see Whitlow et al (1991) 35 Methods companion Methods Enzymol, 2, 97-105 and Huston et al (1993) Int.Rev.lmmunol 10, 195-217. ScFv may be produced in bacterial cells such as E.Coli 27 WO 2010/017468 PCT/US2009/053136 but are more typically produced in eukaryotic cells. One disadvantage of ScFv is the monovalency of the product, which precludes an increased avidity due to polyvalent binding, and their short half-life. Attempts to overcome these problems include bivalent (ScFv') 2 produced from ScFV containing an additional C terminal cysteine by chemical 5 coupling ( Adams et al (1993) Can.Res 53, 4026-4034 and McCartney et al (1995) Protein Eng. 8, 301-314) or by spontaneous site-specific dimerization of ScFv containing an unpaired C terminal cysteine residue (see Kipriyanov et al (1995) Cell. Biophys 26, 187-204). Alternatively, ScFv can be forced to form multimers by shortening the peptide linker to between 3 to 12 residues to form "diabodies", see Holliger et al PNAS (1993), 90, 10 6444-6448. Reducing the linker still further can result in ScFV trimers ("triabodies", see Kortt et al (1997) Protein Eng, 10, 423-433) and tetramers ("tetrabodies", see Le Gall et al (1999) FEBS Lett, 453, 164-168). Construction of bivalent ScFV molecules can also be achieved by genetic fusion with protein dimerizing motifs to form "miniantibodies" (see Pack et al (1992) Biochemistry 31, 1579-1584) and "minibodies" (see Hu et al (1996), 15 Cancer Res. 56, 3055-3061). ScFv-Sc-Fv tandems ((ScFV) 2 ) may also be produced by linking two ScFv units by a third peptide linker, see Kurucz et al (1995) J.Immol.154, 4576-4582. Bispecific diabodies can be produced through the noncovalent association of two single chain fusion products consisting of VH domain from one antibody connected by a short linker to the VL domain of another antibody, see Kipriyanov et al (1998), Int.J.Can 20 77,763-772. The stability of such bispecific diabodies can be enhanced by the introduction of disulphide bridges or "knob in hole" mutations as described supra or by the formation of single chain diabodies (ScDb) wherein two hybrid ScFv fragments are connected through a peptide linker see Kontermann et al (1999) J.lmmunol.Methods 226 179-188. Tetravalent bispecific molecules are available by e.g. fusing a ScFv fragment to 25 the CH3 domain of an IgG molecule or to a Fab fragment through the hinge region see Coloma et al (1997) Nature Biotechnol. 15, 159-163. Alternatively, tetravalent bispecific molecules have been created by the fusion of bispecific single chain diabodies (see Alt et al, (1999) FEBS Lett 454, 90-94. Smaller tetravalent bispecific molecules can also be formed by the dimerization of either ScFv-ScFv tandems with a linker containing a helix 30 loop-helix motif (DiBi miniantibodies, see Muller et al (1998) FEBS Lett 432, 45-49) or a single chain molecule comprising four antibody variable domains (VH and VL) in an orientation preventing intramolecular pairing (tandem diabody, see Kipriyanov et al, (1999) J.Mol.Biol. 293, 41-56). Bispecific F(ab')2 fragments can be created by chemical coupling of Fab' fragments or by heterodimerization through leucine zippers (see Shalaby 35 et al, (1992) J.Exp.Med. 175, 217-225 and Kostelny et al (1992), J.lmmunol. 148, 1547 28 WO 2010/017468 PCT/US2009/053136 1553). Also available are isolated VH and VL domains, see US 6, 248,516; US 6,291,158; US 6, 172,197. Other Modifications. 5 The binding proteins of the present invention may comprise other modifications to enhance or change their effector functions. The interaction between the Fc region of an antibody and various Fc receptors (FcyR) is believed to mediate the effector functions of the antibody which include antibody-dependent cellular cytotoxicity (ADCC), fixation of complement, phagocytosis and half-life/clearance of the antibody. Various modifications 10 to the Fc region of antibodies of the invention may be carried out depending on the desired effector property. In particular, human constant regions which essentially lack the functions of a) activation of complement by the classical pathway; and b) mediating antibody-dependent cellular cytotoxicity include the IgG4 constant region, the IgG2 constant region and IgG1 constant regions containing specific mutations as for example 15 mutations at positions 234, 235, 236, 237, 297, 318, 320 and/or 322 disclosed in EP0307434 (W08807089), EP 0629 240 (W09317105) and WO 2004/014953. Mutations at residues 235 or 237 within the CH2 domain of the heavy chain constant region (Kabat numbering; EU Index system) have separately been described to reduce binding to FcyRI, FcyRII and FcyRlIl binding and therefore reduce antibody-dependent cellular 20 cytotoxicity (ADCC) (Duncan et al. Nature 1988, 332; 563-564; Lund et al. J. Immunol. 1991, 147; 2657-2662; Chappel et al. PNAS 1991, 88; 9036-9040; Burton and Woof, Adv. Immunol. 1992, 51;1-84; Morgan et al., Immunology 1995, 86; 319-324; Hezareh et al., J. Virol. 2001, 75 (24); 12161-12168). Further, some reports have also described involvement of some of these residues in recruiting or mediating complement dependent 25 cytotoxicity (CDC) (Morgan et al., 1995; Xu et al., Cell. Immunol. 2000; 200:16-26; Hezareh et al., J. Virol. 2001, 75 (24); 12161-12168). Residues 235 and 237 have therefore both been mutated to alanine residues (Brett et al. Immunology 1997, 91; 346 353; Bartholomew et al. Immunology 1995, 85; 41-48; and W09958679) to reduce both complement mediated and FcyR-mediated effects. Antibodies comprising these constant 30 regions may be termed 'non-lytic' antibodies. One may incorporate a salvage receptor binding epitope into the antibody to increase serum half life see US 5,739,277. Human Fcy receptors include FcyR (1), FcyRlla, FcyRllb, FcyRlIla and neonatal FcRn. Shields et al, (2001) J.Biol.Chem 276, 6591-6604 demonstrated that a common 35 set of IgG1 residues is involved in binding all FcyRs, while FcyRlI and FcyRlIl utilize 29 WO 2010/017468 PCT/US2009/053136 distinct sites outside of this common set. One group of IgG1 residues reduced binding to all FcyRs when altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 and Pro-239. All are in the IgG CH2 domain and clustered near the hinge joining CH1 and CH2. While FcyRI utilizes only the common set of IgG1 residues for binding, FcyRlI and FcyRlIl 5 interact with distinct residues in addition to the common set. Alteration of some residues reduced binding only to FcyRlI (e.g. Arg-292) or FcyRlIl (e.g. Glu-293). Some variants showed improved binding to FcyRlI or FcyRlIl but did not affect binding to the other receptor (e.g., Ser-267Ala improved binding to FcyRlI but binding to FcyRlIl was unaffected). Other variants exhibited improved binding to FcyRlI or FcyRIII with reduction 10 in binding to the other receptor (e.g. Ser-298Ala improved binding to FcyRIII and reduced binding to FcyRlI). For FcyRlIla, the best binding IgG1 variants had combined alanine substitutions at Ser-298, Glu-333 and Lys-334. The neonatal FcRn receptor is believed to be involved in protecting IgG molecules from degradation and thus enhancing serum half life and the transcytosis across tissues (see Junghans R.P (1997) Immunol.Res 16. 15 29-57 and Ghetie et al (2000) Annu.Rev.lmmunol. 18, 739-766). Human IgG1 residues determined to interact directly with human FcRn include lle253, Ser254, Lys288, Thr307, Gln31 1, Asn434 and His435. The therapeutic antibody of the invention may incorporate any of the above constant region modifications. 20 In a particular embodiment, the therapeutic antibody essentially lacks the functions of a) activation of complement by the classical pathway; and b) mediating antibody-dependent cellular cytotoxicity. In a more particular embodiment, the present invention provides therapeutic antibodies of the invention having any one (or more) of the residue changes detailed above to modify half-life/clearance and/or effector functions 25 such as ADCC and/or complement dependent cytotoxicity and/or complement lysis. In a further aspect of the present invention, the therapeutic antibody has a constant region of isotype human IgG1 with alanine (or other disrupting) substitutions at positions 235 (e.g., L235A) and 237 (e.g., G237A) (numbering according to the EU scheme outlined in Kabat). 30 Other derivatives of the invention include glycosylation variants of the antibodies of the invention. Glycosylation of antibodies at conserved positions in their constant regions is known to have a profound effect on antibody function, particularly effector functioning, such as those described above, see for example, Boyd et al (1996), Mol.lmmunol. 32, 1311-1318. Glycosylation variants of the therapeutic antibodies of the 30 WO 2010/017468 PCT/US2009/053136 present invention wherein one or more carbohydrate moiety is added, substituted, deleted or modified are contemplated. Analogs 5 In this context of the present invention, also provided are analogs of the antibodies described. Thus, the invention provides analogs of the R34.34, GR34, 9B7, 6A3, 1A11 or 6C5 CDRs (R34.34 analogs, GR34 analogs, 9B7 analogs, 6A3 analogs, A1 1 analogs or 6C5 analogs). Analogs of a parental antibody (e.g. 6A3 or 9B7) will have the same or similar functional properties to those containing the CDRs of the 10 parental antibody, respectively, in that the 9B7 analog antibodies or 6A3 analog antibodies bind to the same target protein or epitope with the same or similar binding affinity. The analogs may comprise one or more amino acid substitutions within each or all of its CDRs, and in one embodiment at least 75% or 80% of the amino acid residues in the CDRs of the parental antibody are unaltered, in another embodiment at least 90% of 15 the CDRs are unaltered, and in another embodiment at least 95% of the amino acid residues in the CDRs are unaltered. In another embodiment, the CDR H3 of the parental antibody is unaltered in its entirety, whilst the other CDRs may be the same as the corresponding parental antibody CDRs or may be analogs thereof. 20 Production Methods The binding proteins of the present invention may be produced by methods known to the man skilled in the art. Antibodies of the present invention may be produced in transgenic organisms such as goats (see Pollock et al (1999), J.lmmunol.Methods 231:147-157), chickens (see Morrow KJJ (2000) Genet.Eng.News 20:1-55), mice (see 25 Pollock et al ibid) or plants (see Doran PM, (2000) Curr.Opinion Biotechnol. 11, 199-204, Ma JK-C (1998), Nat.Med. 4; 601-606, Baez J et al, BioPharm (2000) 13: 50-54, Stoger E et a; (2000) Plant Mol.Biol. 42:583-590). Antibodies may also be produced by chemical synthesis. However, antibodies of the invention are typically produced using recombinant cell culturing technology well known to those skilled in the art. A polynucleotide encoding 30 the antibody is isolated and inserted into a replicable vector such as a plasmid for further propagation or expression in a host cell. One useful expression system is a glutamate synthetase system (such as sold by Lonza Biologics), particularly where the host cell is CHO or NSO (see below). Polynucleotide encoding the antibody is readily isolated and sequenced using conventional procedures (e.g. oligonucleotide probes). Vectors that may 35 be used include plasmid, virus, phage, transposons, minichromsomes of which plasmids are a typical embodiment. Generally such vectors further include a signal sequence, 31 WO 2010/017468 PCT/US2009/053136 origin of replication, one or more marker genes, an enhancer element, a promoter and transcription termination sequences operably linked to the light and/or heavy chain polynucleotide so as to facilitate expression. Polynucleotide encoding the light and heavy chains may be inserted into separate vectors and introduced (e.g. by transformation, 5 transfection, electroporation or transduction) into the same host cell concurrently or sequentially or, if desired both the heavy chain and light chain can be inserted into the same vector prior to such introduction. Signal sequences 10 Antibodies of the present invention maybe produced as a fusion protein with a heterologous signal sequence having a specific cleavage site at the N terminus of the mature protein. The signal sequence should be recognised and processed by the host cell. For prokaryotic host cells, the signal sequence may be an alkaline phosphatase, penicillinase, or heat stable enterotoxin || leaders. For yeast secretion the signal 15 sequences may be a yeast invertase leader, a factor leader or acid phosphatase leaders see e.g. W090/13646. In mammalian cell systems, viral secretory leaders such as herpes simplex gD signal and native immunoglobulin signal sequences (such as human Ig heavy chain) are available. Typically the signal sequence is ligated in reading frame to polynucleotide encoding the antibody of the invention. 20 Selection marker Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins e.g. ampicillin, neomycin, methotrexate or tetracycline or (b) complement auxotrophic deficiencies or supply nutrients not available in the complex media or (c) 25 combinations of both. The selection scheme may involve arresting growth of the host cells that contain no vector or vectors. Cells, which have been successfully transformed with the genes encoding the therapeutic antibody of the present invention, survive due to e.g. drug resistance conferred by the co-delivered selection marker. One example is the DHFR-selection system wherein transformants are generated in DHFR negative host 30 strains (eg see Page and Sydenham 1991 Biotechnology 9: 64-68). In this system the DHFR gene is co-delivered with antibody polynucleotide sequences of the invention and DHFR positive cells then selected by nucleoside withdrawal. If required, the DHFR inhibitor methotrexate is also employed to select for transformants with DHFR gene amplification. By operably linking DHFR gene to the antibody coding sequences of the 35 invention or functional derivatives thereof, DHFR gene amplification results in concomitant amplification of the desired antibody sequences of interest. CHO cells are a 32 WO 2010/017468 PCT/US2009/053136 particularly useful cell line for this DHFR/methotrexate selection and methods of amplifying and selecting host cells using the DHFR system are well established in the art see Kaufman R.J. et al J.Mol.Biol. (1982) 159, 601-621, for review, see Werner RG, Noe W, Kopp K,Schluter M," Appropriate mammalian expression systems for 5 biopharmaceuticals", Arzneimittel-Forschung. 48(8):870-80, 1998 Aug. A further example is the glutamate synthetase expression system (Bebbington et al Biotechnology 1992 Vol 10 p169). A suitable selection gene for use in yeast is the trpl gene; see Stinchcomb et al Nature 282, 38, 1979. 10 Promoters Suitable promoters for expressing antibodies of the invention are operably linked to DNA/polynucleotide encoding the antibody. Promoters for prokaryotic hosts include phoA promoter, beta-lactamase and lactose promoter systems, alkaline phosphatase, tryptophan and hybrid promoters such as Tac. Promoters suitable for expression in yeast 15 cells include 3-phosphoglycerate kinase or other glycolytic enzymes e.g. enolase, glyceralderhyde 3 phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose 6 phosphate isomerase, 3-phosphoglycerate mutase and glucokinase. Inducible yeast promoters include alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, metallothionein and enzymes responsible for nitrogen metabolism 20 or maltose/galactose utilization. Promoters for expression in mammalian cell systems include RNA polymerase || promoters including viral promoters such as polyoma, fowlpox and adenoviruses (e.g. adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (in particular the immediate early gene promoter), retrovirus, hepatitis B virus, actin, rous sarcoma 25 virus (RSV) promoter and the early or late Simian virus 40 and non-viral promoters such as EF-1alpha (Mizushima and Nagata Nucleic Acids Res 1990 18(17):5322. The choice of promoter may be based upon suitable compatibility with the host cell used for expression. 30 Enhancer element Where appropriate, e.g. for expression in higher eukaroytics, additional enhancer elements can be included instead of or as well as those found located in the promoters described above. Suitable mammalian enhancer sequences include enhancer elements from globin, elastase, albumin, fetoprotein, metallothionine and insulin. Alternatively, one 35 may use an enhancer element from a eukaroytic cell virus such as SV40 enhancer, cytomegalovirus early promoter enhancer, polyoma enhancer, baculoviral enhancer or 33 WO 2010/017468 PCT/US2009/053136 murine IgG2a locus (see W004/009823). Whilst such enhancers are typically located on the vector at a site upstream to the promoter, they can also be located elsewhere e.g. within the untranslated region or downstream of the polyadenylation signal. The choice and positioning of enhancer may be based upon suitable compatibility with the host cell 5 used for expression. Polyadenylation/Termination In eukaryotic systems, polyadenylation signals are operably linked to polynucleotide encoding the antibody of this invention. Such signals are typically placed 10 3' of the open reading frame. In mammalian systems, non-limiting example signals include those derived from growth hormones, elongation factor-1 alpha and viral (eg SV40) genes or retroviral long terminal repeats. In yeast systems non-limiting examples of polydenylation/termination signals include those derived from the phosphoglycerate kinase (PGK) and the alcohol dehydrogenase 1 (ADH) genes. In prokaryotic systems 15 polyadenylation signals are typically not required and it is instead usual to employ shorter and more defined terminator sequences. The choice of polyadenylation/termination sequences may be based upon suitable compatibility with the host cell used for expression. 20 Other methods/elements for enhanced yields In addition to the above, other features that can be employed to enhance yields include chromatin remodelling elements, introns and host-cell specific codon modification. The codon usage of the antibody of this invention thereof can be modified to accommodate codon bias of the host cell such to augment transcript and/or product yield 25 (eg Hoekema A et al Mol Cell Biol 1987 7(8):2914-24). The choice of codons may be based upon suitable compatibility with the host cell used for expression. Host cells Suitable host cells for cloning or expressing vectors encoding antibodies of the 30 invention are prokaroytic, yeast or higher eukaryotic cells. Suitable prokaryotic cells include eubacteria e.g. enterobacteriaceae such as Escherichia e.g. E.Coli (for example ATCC 31,446; 31,537; 27,325), Enterobacter, Erwinia, Klebsiella Proteus, Salmonella e.g. Salmonella typhimurium, Serratia e.g. Serratia marcescans and Shigella as well as Bacilli such as B.subtilis and B.licheniformis (see DD 266 710), Pseudomonas such as 35 P.aeruginosa and Streptomyces. Of the yeast host cells, Saccharomyces cerevisiae, schizosaccharomyces pombe, Kluyveromyces (e.g. ATCC 16,045; 12,424; 24178; 34 WO 2010/017468 PCT/US2009/053136 56,500), yarrowia (EP402, 226), Pichia Pastoris (EP183, 070, see also Peng et al J.Biotechnol. 108 (2004) 185-192), Candida, Trichoderma reesia (EP244, 234), Penicillin, Tolypocladium and Aspergillus hosts such as A.nidulans and A.niger are also contemplated. 5 Although Prokaryotic and yeast host cells are specifically contemplated by the invention, typically however, host cells of the present invention are vertebrate cells. Suitable vertebrate host cells include mammalian cells such as COS-1 (ATCC No.CRL 1650) COS-7 (ATCC CRL 1651), human embryonic kidney line 293, , PerC6 (Crucell), baby hamster kidney cells (BHK) (ATCC CRL.1632), BHK570 (ATCC NO: CRL 10314), 10 293 (ATCC NO.CRL 1573), Chinese hamster ovary cells CHO (e.g. CHO-K1, ATCC NO: CCL 61, DHFR minus CHO cell line such as DG44 (Urlaub et al, Somat Cell Mol Genet (1986) Vol 12 pp555-566), particularly those CHO cell lines adapted for suspension culture, mouse sertoli cells, monkey kidney cells, African green monkey kidney cells (ATCC CRL-1587), HELA cells, canine kidney cells (ATCC CCL 34), human lung cells 15 (ATCC CCL 75), Hep G2 and myeloma or lymphoma cells e.g. NSO (see US 5,807,715), Sp2/0, YO. Thus in one embodiment of the invention there is provided a stably transformed host cell comprising a vector encoding a heavy chain and/or light chain of the therapeutic antibody as described herein. Typically such host cells comprise a first vector encoding 20 the light chain and a second vector encoding said heavy chain. Such host cells may also be further engineered or adapted to modify quality, function and/or yield of the antibody of this invention. Non-limiting examples include expression of specific modifying (eg glycosylation) enzymes and protein folding chaperones. 25 Cell Culturing Methods. Host cells transformed with vectors encoding the therapeutic antibodies of the invention may be cultured by any method known to those skilled in the art. Host cells may be cultured in spinner flasks, shake flasks, roller bottles, wave reactors (eg System 30 1000 from wavebiotech.com) or hollow fibre systems but it is preferred for large scale production that stirred tank reactors or bag reactors (eg Wave Biotech, Somerset, New Jersey USA) are used particularly for suspension cultures. Typically the stirred tankers are adapted for aeration using e.g. spargers, baffles or low shear impellers. For bubble columns and airlift reactors direct aeration with air or oxygen bubbles maybe used. 35 Where the host cells are cultured in a serum free culture media this can be supplemented with a cell protective agent such as pluronic F-68 to help prevent cell damage as a result 35 WO 2010/017468 PCT/US2009/053136 of the aeration process. Depending on the host cell characteristics, either microcarriers maybe used as growth substrates for anchorage dependent cell lines or the cells maybe adapted to suspension culture (which is typical). The culturing of host cells, particularly vertebrate host cells may utilise a variety of operational modes such as batch, fed-batch, 5 repeated batch processing (see Drapeau et al (1994) cytotechnology 15: 103-109), extended batch process or perfusion culture. Although recombinantly transformed mammalian host cells may be cultured in serum-containing media such media comprising fetal calf serum (FCS), it is preferred that such host cells are cultured in serum -free media such as disclosed in Keen et al (1995) Cytotechnology 17:153-163, or 10 commercially available media such as ProCHO-CDM or UltraCHO T M (Cambrex NJ, USA), supplemented where necessary with an energy source such as glucose and synthetic growth factors such as recombinant insulin. The serum-free culturing of host cells may require that those cells are adapted to grow in serum free conditions. One adaptation approach is to culture such host cells in serum containing media and repeatedly 15 exchange 80% of the culture medium for the serum-free media so that the host cells learn to adapt in serum free conditions (see e.g. Scharfenberg K et al (1995) in Animal Cell technology: Developments towards the 21st century (Beuvery E.C. et al eds), pp619-623, Kluwer Academic publishers). Antibodies of the invention secreted into the media may be recovered and purified 20 from the media using a variety of techniques to provide a degree of purification suitable for the intended use. For example the use of therapeutic antibodies of the invention for the treatment of human patients typically mandates at least 95% purity as determined by reducing SDS-PAGE, more typically 98% or 99% purity, when compared to the culture media comprising the therapeutic antibodies. In the first instance, cell debris from the 25 culture media is typically removed using centrifugation followed by a clarification step of the supernatant using e.g. microfiltration, ultrafiltration and/or depth filtration. Alternatively, the antibody can be harvested by microfiltration, ultrafiltration or depth filtration without prior centrifugation. A variety of other techniques such as dialysis and gel electrophoresis and chromatographic techniques such as hydroxyapatite (HA), affinity 30 chromatography (optionally involving an affinity tagging system such as polyhistidine) and/or hydrophobic interaction chromatography (HIC, see US 5, 429,746) are available. In one embodiment, the antibodies of the invention, following various clarification steps, are captured using Protein A or G affinity chromatography followed by further chromatography steps such as ion exchange and/or HA chromatography, anion or cation 35 exchange, size exclusion chromatography and ammonium sulphate precipitation. Typically, various virus removal steps are also employed (e.g. nanofiltration using e.g. a 36 WO 2010/017468 PCT/US2009/053136 DV-20 filter). Following these various steps, a purified (typically monoclonal) preparation comprising at least 10mg/ml or greater e.g. 100mg/ml or greater of the antibody of the invention is provided and therefore forms an embodiment of the invention. Concentration to 100mg/ml or greater can be generated by ultracentrifugation. Suitably such 5 preparations are substantially free of aggregated forms of antibodies of the invention. Bacterial systems are particularly suited for the expression of antibody fragments. Such fragments are localised intracellularly or within the periplasma. Insoluble periplasmic proteins can be extracted and refolded to form active proteins according to methods known to those skilled in the art, see Sanchez et al (1999) J.Biotechnol. 72, 13 10 20 and Cupit PM et al (1999) Lett Appl Microbiol, 29, 273-277. Pharmaceutical Compositions Purified preparations of antibodies of the invention (particularly monoclonal preparations) as described supra, may be incorporated into pharmaceutical compositions 15 for use in the treatment of human diseases and disorders such as those outlined above. Typically such compositions further comprise a pharmaceutically acceptable (i.e. inert) carrier as known and called for by acceptable pharmaceutical practice, see e.g. Remingtons Pharmaceutical Sciences, 16th ed, (1980), Mack Publishing Co. Examples of such carriers include sterilised carrier such as saline, Ringers solution or dextrose 20 solution, buffered with suitable buffers such as sodium acetate trihydrate to a pharmaceutically acceptable pH, such as a pH within a range of 5 to 8. Pharmaceutical compositions for injection (e.g. by intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular or intraportal) or continuous infusion are suitably free of visible particulate matter and may comprise from 1mg to 10g of therapeutic antibody, 25 typically 5mg to 1g, more specifically 5mg to 25mg or 50mg of antibody. Methods for the preparation of such pharmaceutical compositions are well known to those skilled in the art. In one embodiment, pharmaceutical compositions comprise from 1mg to 10g of therapeutic antibodies of the invention in unit dosage form, optionally together with instructions for use. Pharmaceutical compositions of the invention may be lyophilised 30 (freeze dried) for reconstitution prior to administration according to methods well known or apparent to those skilled in the art. Where embodiments of the invention comprise antibodies of the invention with an IgG1 isotype, a chelator of metal ions including copper, such as citrate (e.g. sodium citrate) or EDTA or histidine, may be added to the pharmaceutical composition to reduce the degree of metal-mediated degradation of 35 antibodies of this isotype, see EP0612251. Pharmaceutical compositions may also 37 WO 2010/017468 PCT/US2009/053136 comprise a solubiliser such as arginine base, a detergent/anti-aggregation agent such as polysorbate 80, and an inert gas such as nitrogen to replace vial headspace oxygen. Effective doses and treatment regimes for administering the antibody of the invention are generally determined empirically and are dependent on factors such as the 5 age, weight and health status of the patient and disease or disorder to be treated. Such factors are within the purview of the attending physican. Guidance in selecting appropriate doses may be found in e.g. Smith et al (1977) Antibodies in human diagnosis and therapy, Raven Press, New York. 10 Clinical uses The antagonists of the present invention may be used in the therapy of multiple sclerosis and in other autoimmune or inflammatory diseases, particularly those in which pathogenic TH1 7 cells are implicated. Such diseases are associated with high levels of IL-17 expression. Elevated levels of IL-17 have been reported in serum and CSF of MS 15 patients (Matusevicius, D. et al.; Mult. Scler. 5, 101-104; 1999) and in the synovial fluid obtained from rheumatoid arthritis patients. IL-17 has also been implicated in psoriasis (Homey et al.; J. Immunol. 164(12):6621-32; 2000), while Hamzaoui et al reported high levels of IL-17 in Behcet's disease (Scand. J. Rhuematol.; 31:4, 205-210; 2002). Elevated IL-17 levels have also been observed in systemic lupus erythrematosus (SLE) 20 (Wong et al.; Lupus 9(8):589-93; 2000). Inhibition of IL-7 receptor mediated signalling may also be useful in the treatment of inflammatory (non-autoimmune) diseases in which elevated IL-17 has been implicated, such as asthma. Accordingly, inflammatory and/or autoimmune diseases of the invention include 25 inflammatory skin diseases including psoriasis and atopic dermatitis; systemic scleroderma and sclerosis; inflammatory bowel disease (IBD); Crohn's disease; ulcerative colitis; ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary 30 angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjorgen's syndrome, vasculitis; 35 diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; alcoholic 38 WO 2010/017468 PCT/US2009/053136 hepatitis; bacterial pneumonia; antigen-antibody complex mediated diseases including glomerulonephritis; sepsis; sarcoidosis; immunopathologic responses to tissue/organ transplantation; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, hypersensitivity 5 pneumonitis, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis; psoriatic arthritis; neuromyelitis optica, Guillain-Barre syndrome (GBS), COPD, type 1 diabetes, etc. In particular, the antagonists of the present invention may be useful in the therapy of multiple sclerosis, in all its forms, including neuromyelitis optica. Treatment with an antagonist of the present invention is predicted to be most efficacious when administered 10 in the context of active inflammatory disease, i.e. when used in the treatment of clinically isolated syndrome or relapsing forms of MS. These stages of disease can be defined clinically and/or by imaging criteria such as gadolinium enhancement or other more sensitive techniques, and/or other as yet undefined biomarkers of active disease. Particularly, the antagonists of the invention can be used to treat RRMS (via intravenous, 15 sub-cutaneous, oral or intramuscular delivery) when the patients are entering or are in relapse. In an embodiment, the antagonist of the invention is administered to the patient at the onset of relapse, or within 1hr, 2hrs, 3hrs, 6hrs, 12hrs, 24hrs, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days from the onset of relapse. The use of biomarkers such as CD127 expression and intracellular cytokine 20 staining (e.g. IL-17 staining) provides criteria for applying the therapeutic anti-CD127 binding protein. A subgroup of MS patients with increased TH1 7 in their CD4+ T cells are primary candidates for the treatment. In one embodiment the methods of treatment are methods of the present invention are methods to treat those patients that express high level of CD127 on their T cells, making them susceptible to anti-CD127 treatment. 25 Treatment with anti-CD127 may likely shorten the time of relapse and quicken the attenuation of the clinical activities measurable by EDSS or MRI. Once the patients enter remission, the treatment may be stopped to avoid complications such as the inhibition of normal T cell development and homeostasis. The use of the anti-CD127 antibody may also prolong the period between relapses and improve patients' quality of life. 30 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly used and understood by those of ordinary skill in the art. The examples, and the materials used therein are for the purposes of illustration only and are not intended to be limiting. 39 WO 2010/017468 PCT/US2009/053136 Description SEQ ID NO: Human CD127 amino acid sequence 1 9B7 Heavy chain variable region 2 9B7 Light chain variable region 3 9B7 CDR H1 4 9B7 CDR H2 5 9B7 CDR H3 6 9B7 CDR Li 7 9B7 CDR L2 8 9B7 CDR L3 9 Epitope of SB/14 (171-187 mouse CD127) 10 Epitope of A7R34 (80-95 mouse CD127) 11 9B7 Heavy chain FR1 sequence 12 9B7 Heavy chain FR2 sequence 13 9B7 Heavy chain FR3 sequence 14 9B7 Heavy chain FR4 sequence 15 9B7 Light chain FR1 sequence 16 9B7 Light chain FR2 sequence 17 9B7 Light chain FR3 sequence 18 9B7 Light chain FR4 sequence 19 9B7 epitope by peptide ELISA 20 9B7 epitope by peptide ELISA 21 9B7 epitope by peptide ELISA 22 9B7 Phage epitope region 1 23 9B7 Phage epitope region 2 24 9B7 Phage epitope region 3 25 9B7 Consensus epitope region 1 26 9B7 Consensus epitope region 2 27 9B7 Consensus epitope region 3 28 6C5 Heavy chain variable region 29 6C5 Light chain variable region 30 6C5 CDR H1 31 6C5 CDR H2 32 6C5 CDR H3 33 40 WO 2010/017468 PCT/US2009/053136 6C5 CDR Li 34 6C5 CDR L2 35 6C5 CDR L3 36 6C5 Heavy chain FR1 sequence 37 6C5 Heavy chain FR2 sequence 38 6C5 Heavy chain FR3 sequence 39 6C5 Heavy chain FR4 sequence 40 6C5 Light chain FR1 sequence 41 6C5 Light chain FR2 sequence 42 6C5 Light chain FR3 sequence 43 6C5 Light chain FR4 sequence 44 6C5 Epitope by BlAcore 45 6C5 Phage epitope region 1 46 6C5 Phage epitope region 2 47 6C5 Consensus epitope region 1 48 6C5 Consensus epitope region 2 49 6C5 Consensus epitope region 3 50 6A3 Heavy chain variable region 51 6A3 Light chain variable region 52 6A3 CDR H1 53 6A3 CDR H2 54 6A3 CDR H3 55 6A3 CDR Li 56 6A3 CDR L2 57 6A3 CDR L3 58 6A3 Heavy chain FR1 sequence 59 6A3 Heavy chain FR2 sequence 60 6A3 Heavy chain FR3 sequence 61 6A3 Heavy chain FR4 sequence 62 6A3 Light chain FR1 sequence 63 6A3 Light chain FR2 sequence 64 6A3 Light chain FR3 sequence 65 6A3 Light chain FR4 sequence 66 6A3 Phage epitope region 1 67 41 WO 2010/017468 PCT/US2009/053136 6A3 Phage epitope region 2 68 6A3 Phage epitope region 3 69 6A3 Phage epitope region 4 70 A1 1 Heavy chain variable region 71 A1 1 Light chain variable region 72 1A11 CDR H1 73 1A1 CDR H2 74 1A1 CDR H3 75 1A11 CDR L1 76 1A1 CDR L2 77 1A1 CDR L3 78 A1 1 Heavy chain FR1 sequence 79 A1 1 Heavy chain FR2 sequence 80 A1 1 Heavy chain FR3 sequence 81 A1 1 Heavy chain FR4 sequence 82 A1 1 Light chain FR1 sequence 83 A1 1 Light chain FR2 sequence 84 A1 1 Light chain FR3 sequence 85 A1 1 Light chain FR4 sequence 86 A1 1 Phage epitope region 1 87 A1 1 Phage epitope region 2 88 A1 1 Phage epitope region 3 89 GR34 Heavy chain variable region 90 GR34 Light chain variable region 91 GR34 CDR H1 92 GR34 CDR H2 93 GR34 CDR H3 94 GR34 CDR Li 95 GR34 CDR L2 96 GR34 CDR L3 97 GR34 Heavy chain FR1 sequence 98 GR34 Heavy chain FR2 sequence 99 GR34 Heavy chain FR3 sequence 100 GR34Heavy chain FR4 sequence 101 42 WO 2010/017468 PCT/US2009/053136 GR34 Light chain FR1 sequence 102 GR34 Light chain FR2 sequence 103 GR34 Light chain FR3 sequence 104 GR34 Light chain FR4 sequence 105 R.34.34 Epitope by BlAcore region 1 106 R.34.34 Epitope by BlAcore region 2 107 R.34.34 Epitope by BlAcore region 3 108 R.34.34 Epitope by BlAcore region 4 109 R.34.34 Epitope by BlAcore region 5 110 R.34.34 Phage epitope region 1 111 R.34.34 Phage epitope region 2 112 R.34.34 Phage epitope region 3 113 R.34.34 Consensus epitope region 1 114 R.34.34 Consensus epitope region 2 115 R.34.34 Consensus epitope region 3 116 CD127 Epitope region 1 117 CD127 Epitope region 2 118 CD127 Epitope region 3 119 CD127 Epitope region 4 120 CD127 Epitope region 5 121 CD127 Epitope region la 122 CD127 Epitope region 2a 123 CD127 Epitope region 3a 124 CD127 Epitope region 4a 125 CD127 Epitope region 5a 126 Example 1: Characterization of monoclonal antibodies that bind to mouse CD127 Methods 5 1.1 Evaluation of commercially available mouse antibodies to mouse CD127 by using FACS on pStat5 detection assay In this example, we identified commercially available anti-mouse CD127 antibodies that inhibited IL-7-induced Stat5 phosphorylation (pStat5). Briefly, splenocytes 10 were prepared from C57B/6 mouse spleens by a standard protocol; CD4' T cells were 43 WO 2010/017468 PCT/US2009/053136 then purified from the splenocytes using a Miltenyi magnetic isolation kit (Cat# 130-049 201); one million CD4' T cells per ml were first incubated with the indicated antibodies and concentrations as shown in the figure below for 30 min. at 370C; the antibodies used were BD Biosciences control rat IgG2a (#553926), BD Biosciences anti-CD127 (Clone 5 SB/14, #550426), eBiosciences anti-CD127 (Clone:A7R34, #16-1271), Abcam anti CD127 (Clone SB199, #ab36428), R&D anti-CD127 (MAB7471 and 7472) ; cells were then either untreated or treated with 1 ng/ml mouse IL-7 for 60 min. at 370C; cells were collected and immediately put on ice after the IL-7 treatment; cells were then washed with ice-cold PBS once and fixed in 1% paraformaldehyde for 10 min. at 370C; cells were 10 washed with PBS and incubated with 500pl 90% methanol/PBS for 30 min. on ice; cells were washed again in PBS and cell pellets were resuspended in 100ul PBS; cells were stained by 5ul of anti-pStat5-Alexa Fluor 647 antibody (BD Biosciences, #612599) for 1 h in RT in the dark; cells were then washed two times with PBS and analyzed by flow cytometry with a BD Biosciences Facscalibur machine according to the manufacturer's 15 instructions. The results are shown in Figure 1. In the graphs, cell numbers were plotted against mean fluorescence intensity (MFI) of intracellular pStat5. The histograms showed the MFI of untreated CD4' T cells. Treatment with IL-7 shifted the MFI to the right and cells with increased pStat5 were defined by the appropriate gate as shown by the bar in the histogram. The control IgG 20 did not inhibit pStat5. However, A7R34 strongly inhibited pStat5. The antibody clone SB/14 also showed inhibition although it was not as strong as A7R34. The abcam clone SB199 and the R&D systems antibodies could only inhibit Stat5-p partially at high concentration. SB/14 was also tested for its inhibition of IL-7-driven expansion of differentiated 25 TH1 7 in vitro. Experimental autoimmune encephalomyelitis (EAE) was induced in mice by immunization of myelin oligodendrocyte glycoprotein (MOG) as described in Example 3 below. CD4+ T cells were harvested from the spleens or lymph nodes of EAE mice and were cultured in vitro in the absence or presence of IL-7 for 3 days. As shown in Figure 11C, IL-7 promoted the expansion of TH1 7 cells, detectable by IL-17 intracellular staining. 30 Antibody SB/14 against mouse IL-7Ra but not a control IgG inhibited the IL-7-driven expansion of Th17 cells. The antibodies were also tested for the inhibition of TSLP-mediated pStat5 in mouse thymocytes. CD4- cells in thymocytes expressed functional TSLP receptors and were gated in the FACS analysis. As shown in Figure 1B, IL-7-induced and TSLP 35 induced pStat5 was inhibited by SB/14 (BD) and A7R34 (eBio). Therefore, antibodies 44 WO 2010/017468 PCT/US2009/053136 against mouse CD127 (SB/14 and A7R34) inhibited both IL-7- mediated and TSLP mediated signalling. 1.2 Identification of epitope by peptide ELISA 5 15 mers with 7 overlapping peptides of mouse IL7RECD were synthesized by Shanghai Science peptide Biology Technology, and by GL Biochem (Shanghai) Ltd. All peptides were prepared by continuous-flow solid phase peptide synthesis. The peptides were then biotinylated at the N-terminus of the peptide with a spacer Acp between the 10 peptide and the biotin moiety, i.e., biotin-Acp-peptide. The wells of a 96-well plate with 1OOuL of lug/mL each testing antibody in carbonate buffer (15 mM Na 2

CO

3 , 35 mM NaHCO 3 , 0.2 g/L NaN 3 , at pH 9.6) was coated for overnight at 4'C. Next day plate was washed three times 200 pl/well with wash buffer (1X PBS containing 0.05% Tween-20) and 200 pl/well blocking buffer (10 mg/ml bovine 15 serum albumin (BSA) in PBST) was incubated for 1 hour at 37'C. After washing the plate three times, 100uL of 2ug/mL synthetic biotinylated peptide was applied at 37'C for 1 hour. After three washes, 100uL/well of 1/2000 diluted HRP-SA was added and incubated at 37'C for 30 minutes. 100uL/well of TMB substrate solution was used after five washes. Incubation was 2 to 5 min at RT before stopped with 2N HCI. Read plate at 450 nm with 20 an appropriate time-resolved plate reader. 1.3 Prediction of epitopes by biopanning phage peptide display Random peptide libraries displayed on filamentous bacteriophage M13 has been used as 25 a tool to map the epitopes of monoclonal antibodies (Scott and Smith, 1990, searching for peptide ligands with an epitope library, Science, 249:386-390). We have used a commercial phage-displayed random peptide library and an in house phage-displayed random peptide library to identify phage peptides that bind to mouse antibody. Enriched phage displayed peptide consensus sequences or mimotopes from identified phage 30 peptides were employed to predict possible epitopes of mouse antibody (phage peptide mimotopes: antibody interaction site on the surface of the antigen mimicked by phage peptide or a mimic of an epitope) (Geysen et al., 1986, a priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol. Immunol., 23:709-715; Luzzago et al., 1993, mimicking of discontinuous epitopes by phage-displayed peptides, I. 35 Epitope mapping of human H ferritin using a phage library of constrained peptides, Gene, 45 WO 2010/017468 PCT/US2009/053136 128: 51-57). Phage peptide mimotopes identified from the 2 random libraries predicted 2 possible discontinuous epitopes of mouse antibody. Random peptide libraries: 5 1. Ph.D-12 phage displayed random peptide library (from New England Biolabs Inc., #E8110S) 2. fGWX10 phage displayed random peptide library (GSK in house library) Biopanning procedure using Ph.D-12 phage displayed random peptide library: 10 Biopanning of Ph.D-12 phage displayed random peptide library against immobilized mAb 9B7 was conducted essentially according to the manufacturer's instruction manual. Briefly: 1) Coat 100 pg/ml of each testing antibody (in 0.1 M NaHCO 3 , pH 8.6) to the well of the 12-well plate and incubate overnight at 4'C with gentle agitation. 2) Incubate with blocking Buffer (0.1M NaHCO 3 , pH8.6, 5mg/ml BSA, 0.02 NaN 3 was 15 used for the anti-mouse antibody procedures; 1% milk was subsequently used for the anti-human antibody procedures) for 1 hour at 4'C and then TBST wash for six times (TBS + 0.1% [v/v] Tween-20). 3) Apply diluted 4 x 1010 phage in TBST onto coated plate and rock gently for 60 minutes at room temperature. 20 4) Discard nonbinding phage and wash plates 10 times with TBST. 5) Elute bound phage with 300ul 0.2 M Glycine-HCI (pH 2.2), 1 mg/ml BSA and neutralize with 45 pl 1 M Tris-HCI (pH 9.1) for further two rounds of biopanning. 6) Add the eluate to the inoculated E. coli. ER2738 culture and incubate at 37'C with vigorous shaking for 4.5 hours. Centrifuged cultured supernatant then precipitate in 25 PEG/NaCI at 4'C for overnight. 7) Titer the resulting third round amplified eluate on LB/IPTG/Xgal plates. Plaques from titering plates were used for DNA sequencing. The biopanning procedure using fGWX10 phage displayed random peptide library: 30 The in house phage library, fGWX10, displaying 10-mer random peptide sequences was constructed as described previously (Deng et al., 2004, Identification of peptides that inhibit the DNA binding, trans-activator, and DNA replication functions of the human papillomavirus type 11 E2 protein, J. Virol., 78: 2637-2641). Briefly, 1) Coat 100 pg/ml of each testing antibody (in 0.1 M NaHCO 3 , pH 8.6) to the well of the 35 12-well plate and incubate overnight at 4'C with gentle agitation. 2) Inoculate one tube with 10 ml LB medium with E. coli K91. Incubate culture at 37'C 46 WO 2010/017468 PCT/US2009/053136 with vigorous shaking. 3) Incubate with blocking Buffer (0.1M NaHCO 3 , pH8.6, 5mg/ml BSA, 0.02 NaN 3 was used for the anti-mouse antibody procedures; 1% milk was subsequently used for the anti-human antibody procedures) for 1 hour at 4'C and then TBST wash for six times 5 (TBS + 0.1% [v/v] Tween-20). 4) Apply diluted 50 ul fGWX10 phage (diversity 1x0 10 ) with 350 ml of TBST onto coated plate and rock gently for 60 minutes at room temperature and wash plates 10 times with TBST 5) Elute bound phage with 300ul 0.2 M Glycine-HCI (pH 2.2), 1 mg/ml BSA into a 10 microcentrifuge tube and neutralize with 45 pl 1 M Tris-HCI, pH 9.1 for further two rounds of biopanning. 6) Titer the unamplified third round eluate using inoculated E coli K91 cells on LB/Tet plates. Colony from titering was used for DNA sequencing. Store the remaining eluate at 4'C. 15 1.4 Determination of epitope binding of mouse antibody by Biacore The binding epitope of anti-mouse CD127 antibodies for mouse CD127 were assessed using a Biacore T100 system (GE Healthcare). Briefly, anti-mouse CD127 antibodies was 20 immobilized on a CM5 biosensor chip with a final level of -100 RU (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 7.4 (consisting of 10 mM HEPES, 0.15 M sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was activated/deactivated using EDC/NHS/ethanol amine. 15 mers with 7 overlapping 25 peptides of IL7R ECD were synthesized by Shanghai Science peptide Biology Technology, and by GL Biochem (Shanghai) Ltd. Each peptide was injected at various concentrations for 120s at a flow rate of 30uL/min. Kd values were calculated using the Biacore evaluation software package. The runs were carried out at 25'C. Table 1 shows epitope regions of mouse CD127 (NP_032398) for two mouse 30 antibodies, BD Biosciences Clone SB/14 and eBiosciences Clone A7R34 that identified by one or more of the methods phage peptide library, peptide ELISA and Biacore 47 WO 2010/017468 PCT/US2009/053136 Table 1: Summary of epitope studies for anti-murine CD127 antibodies SB/14 and A7R34 Antibody Mouse epitope BlAcore Phage Peptide library ELISA SB/14 171-PARGESNWTHVSLFHTR-187 (SEQ ID NO: 10) A7R34 80-VKCLTLNKLQDIYFIK-95 N/D 1 N/D (SEQ ID NO:11) 5 Example 2: Generation of monoclonal antibodies that bind to human CD127 (hCD127) Monoclonal antibodies (mAbs) were produced by hybridoma cells generally in accordance with the method set forth in E Harlow and D Lane, Antibodies a Laboratory Manual, Cold Spring Harbor Laboratory, 1988. 10 Antigen used to generate hybridomas including 9B7 and 6C5 was a dimeric recombinant human CD127 extracellular domain (ECD)-Fc (R&D Systems #306-IR), comprising amino acid 21-262 of human CD127 (SEQ ID No:1). Antigen used to generate hybridomas including 6A3 and A1 1 was a construct containing the full ECD of CD127 (amino acids 21-219 of SEQ ID NO:1). 15 Balb/c mice were primed and boosted by intraperitoneal injection with Antigen in FCA or FIA (Sigma-Aldrich, #F5881, #F5506) (1:1; vol:vol). Spleens from responder animals were harvested and fused to SP/O myeloma cells to generate hybridomas. Hybridomas of interest were monocloned using semi-solid media (methyl cellulose solution) and manually picked up into 96-well plate. The hybridoma supernatant material 20 was screened for binding to CD127ECD using ELISA, CHO-CD127 transfected cell FACS, pStat5 FACS and BlAcore T1 00 (results shown below). Selected purified mAbs (isolated from hybridoma supernatants 9B7, 6C5, 6A3 and 1A11) were tested for inhibition of IL-7 induced IFN-y and IL-17 in a TH1 7 expansion assay. In addition, commercially available anti-hCD127 R34.34 was shown to inhibit IL-7 25 induced IFN-y and IL-17 in a TH1 7 expansion assay and was also selected for further analysis. 48 WO 2010/017468 PCT/US2009/053136 Methods 2.1 Selection of Hybridoma Binding to CD127 by ELISA 5 pg/ml recombinant human CD127ECD was coated onto an ELISA plate. Anti 5 CD127 antibodies from the test hybridoma supernatants or purified material were titrated across the plate. The level of binding was detected by treatment with a horse-radish peroxidase (HRP) -conjugated goat-anti-mouse IgG antibody. The ELISA was developed using TMB substrate. Results for the 9B7 hybridoma supernatant are shown in Figure 2. 10 2.2 Fluorescence Activated Cell Sortinq (FACS) analysis Mock transfected CHO or CHO-CD127 cells (2x10 6 cells/ml) were stained with hybridoma supernatants or purified antibodies at 1 pg/ml for 1 hour with 4% FCS in PBS (FACS buffer). Cells were also stained in a suitable negative control mouse antibody and anti-human CD127 positive control (R34.34 Dendritics Inc. #DDX0700). Cells were 15 washed in FACS buffer and then stained with an anti-mouse IgG ALEXA488 secondary antibody 1:2000 (Invitrogen Inc. #13-A11017). After washing in FACS buffer, cells were analysed in LSR || (BD Biosciences Inc.). Results for the 9B7 antibody are shown in Figure 3. 2.3 Inhibition of IL7 stimulated IL7 receptor signalled Stat5 phosphorVlation by 9B7 20 Defrost Frozen PBMCs the night before the experiment, and leave them in RPMI 1640 medium containing 10% of FBS for recovering. For screening functional antibody to CD127, hybridoma culture medium, positive control antibody (R34.34, Dendritics Inc) at 2ug/ml and 0.2ug/ml, or testing supernatant samples were incubated with 5x10 5 PBMC cells for 30mins before stimulating with 1ng/ml of IL-7. The untreated cells were analyzed 25 as the background signal, while IL-7 treated cells were set as negative control. After 30mins' incubation with the controls or testing samples, the cells were stimulated with 1ng/ml of IL-7 for 15mins at 37'C. Cells then were fixed 1.6% of paraformaldehyde/PBS for 10min at 37'C and were permeabilized in 100% methanol for 20-30 mins. Cells then were washed twice in stain buffer (1% BSA in PBS) and stained with 7ul of Alexa-647 30 labelled anti-pStat5 antibody (BD Biosciences Inc #612599) for 1hr. Samples were analyzed on BD LSR || FACS instrument. Results for 9B7 are shown in Figure 4. An optimised process was used to utilised for antibodies R34.34, 6A3, A1 1 and 6C5, as described in Section 3.19. 49 WO 2010/017468 PCT/US2009/053136 2.4 Inhibition of IL-7-induced IL-17 production in human Th17 expansion assay Memory TH1 7 cells in a population of normal human CD4+ T cells are stimulated to expand for three days. These TH1 7 cells are then activated by PMA and ionomycin to stimulate the production of IL-17. Blocking the interaction between the IL-7 and CD127 5 by a functional anti-CD127 antibody in the three day incubation period should prevent the expansion of the TH1 7 cells leading to the reduction of IL-17 production. CD4+ T cells were isolated from human peripheral blood mononuclear cells using a commercial kit (CD4+ T Cell Isolation Kit II, # 130-091-155, Miltenyi Biotec). CD4+ T cells were resuspended in RPMI medium with 10% FCS at a concentration of 10 1.5x1OE6/ml. Cells were pre-incubated with control or anti-IL-7Ra antibodies for 30 min. Cells were then cultured with or without 10 ng/ml of IL-7 for 72 h at 37 C. At the end of the incubation, cells were stimulated with 50ng/ml PMA and 1 ug/ml of lonomycin for 5 h. Cell culture supernatants were then collected and the IL-17 concentration were determined by Elisa (eBiosciences). This assay was utilised for antibody 9B7. 15 Antibodies 6C5, 6A3 and R34.34 were assayed according to the following protocol. CD4+ cells were isolated according to the manual (#130-091-155, Miltenyi) . Approximately 1x 10 6 /ml of the CD4+ cells in 100pl were mixed with equal volume of 2x Th17 differentiation medium (2pg/ml anti-CD28 + 10pg/ml anti-IFN-y + 10pg/ml anti-IL-4 + 12.5ng/ml IL-1R + 20ng/ml IL-23 + 50ng/ml IL-6) and cultured in 37'C with 5% CO2 for 5 20 days. Treatment by the various cytokines and growth factors in the TH1 7 medium preferentially differentiated the CD4+ cells into TH1 7 cells. CCR6+ cells from the differentiated cultured cells at day 5 were sorted using BD FACS SORP Aria //. The CCR6+ cells were then adjusted to 2 x10 6 /ml for the IL-17 production assay. To measure IL-17 and IFN-y level, 100pl of CCR6+ cells were pre-incubated with 25 testing antibody for 1h at 37'C, and then mixed with 100pl of 10ng/ml IL-7. The cells were cultured for 24-40 hours in 37'C with supplement of 5% CO. IFN-y and IL-17 levels in 100 ul of culture supernatant were measured by FlowCytomix (Bender MedSystems) at 24 h and 40 h, respectively. 30 2.5 Determination of kinetics of binding by surface plasmon resonance The binding kinetics of anti-CD127 antibodies for human CD127 was assessed using a Biacore T100 system (GE Healthcare). Briefly, recombinant human CD127 ECD was immobilized on a CM5 biosensor chip with a final level of -100 RU (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 7.4 (consisting 35 of 10 mM HEPES, 0.15 M sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was 50 WO 2010/017468 PCT/US2009/053136 activated/deactivated using EDC/NHS/ethanol amine. Analytes (anti-CD127 antibodies) were injected at various concentrations for 120s at a flow rate of 30uL/min. The antigen surfaces were regenerated with 10mM Glycine-HCI, pH2.5. Kd values were calculated using the Biacore evaluation software package. The runs were carried out at 25'C. 5 Table 2. - Kinetic data for supernatant material of 9B7. The run was carried out at 37 0 C. Antibody Ka Kd KD (M) 9B7 8.09E+04 4.50E-05 5.56E-10 The isotype of 9B7 was determined to be IgG1 with a kappa light chain constant region. 10 The following assay was used to evaluate the binding kinetics of anti-CD127 antibodies 6C5, 6A3, 1Al1 and GR34. Antibody kinetics were assessed using a Biacore T100 system (GE Healthcare) with a reaction temperature of 250C. Rabbit anti-mouse IgG antibody was immobilized on a CM5 biosensor chip with a final level of -10000 RU (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 15 7.4 (consisting of 10 mM HEPES, 0.15 M sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was blank immobilized using EDC/NHS/ethanol amine. For ligand capturing, 25nM of 6C5 was injected over the chip surface for 30 s at lOpL/min. Analytes (recombinant human CD127 ECD) were then injected at various concentrations for 500 s 20 at 30 pL/min. The sensor chip surfaces were regenerated with 10 mM Glycine-HCI, pH 1.7. Kd values were calculated using the Biacore evaluation software package. Table 3. Kinetics data for 6C5 and 6A3 ka (1/Ms) kd (1Is) KD (M) 6C5 1.79E+04 4.36E-04 2.44E-08 6A3 1.89E+04 1.46E-04 7.74E-09 1A11 - 2.51E-04 3.44E-09 GR34 - 8.75E-04 15.3E-09 25 2.6 Antibody Profile Summary Antibody 9B7 was found to bind tightly to CD127 with a dissociation constant of 556 pM. It was also capable of partially blocking the binding of IL-7 to CD127, correlating 51 WO 2010/017468 PCT/US2009/053136 to the partial blocking of IL-7-induced STAT-5 phosphorylation in human CD4 cells (Figure 4). Antibody 6C5 (mouse IgG1) was determined to inhibit pSTAT5 signalling with an IC50 of 50 pg/ml. 5 Antibody 6A3 (mouse IgG1) was determined to inhibit pSTAT5 signalling with an IC50 of 0.099pg/ml in the assay described herein. It had an affinity for the IL-7Ra EDC of 7.99nM (KD) and a Kd of 3.34x10 4 . It was capable of binding to IL-7Ra expressed on CHO with an EC 50 of 0.19pg/ml, and blocked IL-7/IL-7Ra with an IC50 of 1.92 pg/ml. 6A3 was determined to bind to amino acids within CD127 epitope regions 2, 3, 4 and 5 (SEQ 10 ID NOs:118-121). Antibody A1 1 (mouse IgG1) was determined to inhibit pSTAT5 signalling with an IC50 of 0.088pg/ml in the assay described herein. It had an affinity for the IL-7Ra EDC of 3.44nM (KD) and a Kd of 2.51x10 4 . It was capable of binding to IL-7Ra expressed on CHO with an EC 50 of 0.16pg/ml, and blocked IL-7/IL-7Ra with an IC50 of 1.79 pg/ml. 15 1A11 was determined to bind to amino acids within CD127 epitope regions 2, 3, 4 and 5 (SEQ ID NOs:118-121). Antibody GR34 (mouse IgG1) was determined to inhibit pSTAT5 signalling with an IC50 of 0.22pg/ml in the assay described herein. It had an affinity for the IL-7Ra EDC of 15.3nM (KD) and a Kd of 8.75x10 4 . It was capable of binding to IL-7Ra expressed on 20 CHO with an EC 50 of 0.27pg/ml, and blocked IL-7/IL-7Ra with an IC50 of 2.29pg/ml. GR34 was determined to bind to amino acids within CD127 epitope regions 2, 3, 4 and 5 (SEQ ID NOs:118-121). Commercial antibody R.3434 (Dendritics) was determined to inhibit pSTAT5 signalling with an IC50 of 0.67pg/ml in the assay described herein. It had an affinity for the 25 IL-7Ra EDC of 7.74nM (KD) and a Kd of 1.46x10 4 . It was capable of binding to IL-7Ra expressed on CHO with an EC 50 of 0.01pg/ml, and blocked IL-7/IL-7Ra with an IC50 of 1.38pg/ml. R.3434 was determined to bind to amino acids within CD127 epitope regions 2, 3, 4 and 5 (SEQ ID NOs:118-121). 30 2.7 Sequencing of Variable domains 2.7.1 9B7 Total RNA was extracted from pellets of 2x1 07 9B7 clone cells using the Oligotex Direct mRNA Kit from Qiagen according to the manufacturer's instruction. The reverse 35 transcription of mRNA to cDNA was performed with ImProm-IITM Reverse Transcription System (Promega) according to the manufacturer's instruction with conventional primers 52 WO 2010/017468 PCT/US2009/053136 for mouse VH and VK genes. 7 reactions for heavy chain variable region and 6 reactions for light chain variable region were amplified. The purified RT-PCR fragments were cloned into pMD18-T vector (Takara) and a consensus sequence was obtained for each hybridoma by sequence alignment, database 5 searching and alignment with known immunoglobulin variable sequences listed in KABAT (Kabat, E.A., Wu, T.T., Perry, H.H., Gottesman, K.S., Foeller, C., 1991. Sequences of proteins of Immunological Interest, 5 th edition, US Department of Health and Human Services, Public Health Service, NIH). 10 The consensus sequence of mAb 9B7 was: Rearranged VH of mAb 9B7 used a V segment of the Igh-VQ52 VH2 family. QVQLQESGPGLVAPSQSLSITCTVSGFSLSRYNVHWVRQPPGKGLEWLGMIWDGGST DYNSALKSRLSITKDNSKSQVFLKMNSLQTDDTAMYYCARNRYESGMDYWGQGTTVT VSS (SEQ ID NO.2) 15 FR1 sequence: QVQLQESGPGLVAPSQSLSITCTVSGFSLS (SEQ ID NO:12) CDR1 sequence: RYNVH (SEQ ID NO:4) FR2 sequence: WVRQPPGKGLEWLG (SEQ ID NO:13) CDR2 sequence: MIWDGGSTDYNSALKS (SEQ ID NO:5) 20 FR3 sequence: RLSITKDNSKSQVFLKMNSLQTDDTAMYYCAR (SEQ ID NO:14) CDR3 sequence: NRYESG (SEQ ID NO:6) FR4 sequence: MDYWGQGTTVTVSS (SEQ ID NO:15) Rearranged Vk of mAb 9B7 used a V segment of the IGKV8 family 25 DIVMTQTPSSLTVTAGEKVTMSCKSSQSLLNSGNRKNYLTWYQQKPGQSPKLLIYWAS TRESGVPDRFTGSGSGTDFTLIISSVQAEDLAVYYCQNDYTYPFTFGSGTKLEIKR (SEQ ID NO:3) FR1 sequence: DIVMTQTPSSLTVTAGEKVTMSC (SEQ ID NO:16) 30 CDR1 sequence: KSSQSLLNSGNRKNYLT (SEQ ID NO:7) FR2 sequence: WYQQKPGQSPKLLIY (SEQ ID NO:17) CDR2 sequence: WASTRES (SEQ ID NO:8) FR3 sequence: GVPDRFTGSGSGTDFTLIISSVQAEDLAVYYC (SEQ ID NO:18) CDR3 sequence: QNDYTYPFTFGS (SEQ ID NO:9) 35 FR 4 sequence: GTKLEIKR (SEQ ID NO:19) 53 WO 2010/017468 PCT/US2009/053136 (CDR regions are in bold. Ig gene: Immunoglobulin gene. VH: Antibody heavy chain variable region. VL: Antibody light chain variable region. FR: Framework region. CDR: Complementarity determining region) 5 2.7.2 6C5 The 6C5 antibody was determined to have the following heavy and light chain variable regions (the CDRs of 6C5, according to Kabat, are shown in bold): Heavy chain variable region of 6C5 10 EVKLLESGGGLVQPGGSLKLSCAASGFAFSAYWMSWVRQAPGKGLEWIGEINPDSSTI NCTPSLKDKFIISRDNAKNTLSLQMNKVRSEDTALYYCARRLRPFWYFDVWGAGTTVTV SS (SEQ ID NO:29) FR1 sequence: EVKLLESGGGLVQPGGSLKLSCAASGFAFS (SEQ ID NO:37) 15 CRDH1 sequence: AYWMS (SEQ ID NO:31) FR2 sequence: WVRQAPGKGLEWIG (SEQ ID NO:38) CDRH2 sequence: EINPDSSTINCTPSLKD (SEQ ID NO:32) FR3 sequence: KFIISRDNAKNTLSLQMNKVRSEDTALYYCAR (SEQ ID NO:39) CDRH3 sequence: RLRPFWYFDVW (SEQ ID NO:33) 20 FR4 sequence: GAGTTVTVSS (SEQ ID NO:40) Light chain variable region of 6C5 DVLMTQTPLSLPVSLGDQASISCRSSQSIVQSNGNTYLEWYLQKPGQSPKLLYKVSNR FSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK (SEQ ID 25 NO: 30) FR1 sequence: DVLMTQTPLSLPVSLGDQASISC (SEQ ID NO:41) CDRL1 sequence: RSSQSIVQSNGNTYLE (SEQ ID NO:34) FR2 sequence: WYLQKPGQSPKLLIY (SEQ ID NO:42) 30 CDRL2 sequence: KVSNRFS (SEQ ID NO:35) FR3 sequence: GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC (SEQ ID NO:43) CDRL3 sequence: FQGSHVPRT (SEQ ID NO:36) FR4 sequence: FGGGTKLEIK (SEQ ID NO:44) 54 WO 2010/017468 PCT/US2009/053136 2.7.3 6A3 The 6A3 antibody was determined to have the following heavy and light chain variable regions (the CDRs of 6A3, according to Kabat, are shown in bold): 5 Heavy chain variable region of 6A3 DVQLQESGPGLVKPSQSLSLTCTVTGYSITTDYAWNWIRQFPGNKLEWMGYIFYSGSTT YTPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARGGYDVNYFDYWGQGTTLTVS S (SEQ ID NO:51) 10 FR1 sequence: DVQLQESGPGLVKPSQSLSLTCTVTGYSIT (SEQ ID NO:59) CRDHi1 sequence: TDYAWN (SEQ ID NO:53) FR2 sequence: WIRQFPGNKLEWMG (SEQ ID NO:60) CDRH2 sequence: YIFYSGSTTYTPSLKS (SEQ ID NO:54) FR3 sequence: RISITRDTSKNQFFLQLNSVTTEDTATYYCAR (SEQ ID NO:61) 15 DRH3 sequence: GGYDVNYF (SEQ ID NO:55) FR4 sequence: DYWGQGTTLTVSS (SEQ ID NO:62) Light chain variable region of 6A3 DIQMTQSPASQSASLGESVTITCLASQTIGAWLAWYQQKPGKSPQLLYAATRLADGVP 20 SRFSGSGSGTKFSFKISSLQAEDFVSYYCQQFFSTPWTFGGGTKLEIK (SEQ ID NO:52) FR1 sequence: DIQMTQSPASQSASLGESVTITC (SEQ ID NO:63) CDRL1 sequence: LASQTIGAWLA (SEQ ID NO:56) FR2 sequence: WYQQKPGKSPQLLIY (SEQ ID NO:64) 25 CDRL2 sequence: AATRLAD (SEQ ID NO:57) FR3 sequence: GVPSRFSGSGSGTKFSFKISSLQAEDFVSYYC (SEQ ID NO:65) CDRL3 sequence: QQFFSTPWT (SEQ ID NO:58) FR4 sequence: FGGGTKLEIK (SEQ ID NO:66) 30 2.7.4 1Al1 The A1 1 antibody was determined to have the following heavy and light chain variable regions (the CDRs of A1 1, according to Kabat, are shown in bold): VH of mAb 1A11 55 WO 2010/017468 PCT/US2009/053136 EVQLQQSGPELLKPGASMKISCKASGYSFTGYTMNWVKQSHGKN LEWI GLINPYNGVT SYNQKFKGKATLTVAKSSSTAYMELLSLTSEDSAVYYCARGDGNYWYFDVWGAGTTVT VSS (SEQ ID NO:71) 5 FR1 sequence: EVQLQQSGPELLKPGASMKISCKASGYSFT (SEQ ID NO:79) CDRH1 sequence: GYTMN (SEQ ID NO:73) FR2 sequence: WVKQSHGKNLEWIG (SEQ ID NO:80) CDRH2 sequence: LINPYNGVTSYNQKFK (SEQ ID NO:74) FR3 sequence: GKATLTVAKSSSTAYMELLSLTSEDSAVYYCAR (SEQ ID NO:81) 10 CDRH3 sequence: GDGNYWYF (SEQ ID NO:75) FR4 sequence: DVWGAGTTVTVSS (SEQ ID NO:82) Vk of mAb 1A11 EIVLTQSPAITAASLGQKVTITCSASSSVTYMHWYQQKSGTSPKPWIYEISKLASGVPVR 15 FSGSGSGTSYSLTISSMEAEDAAYYCQEWNYPYTFGGGTKLEIK (SEQ ID NO:72) FR1 sequence: EIVLTQSPAITAASLGQKVTITC (SEQ ID NO:83) CDRL1 sequence: SASSSVTYMHW (SEQ ID NO:76) FR2 sequence: YQQKSGTSPKPWIY (SEQ ID NO:84) 20 CDRL2 sequence: EISKLAS (SEQ ID NO:77) FR3 sequence: GVPVRFSGSGSGTSYSLTISSMEAEDAAYYC (SEQ ID NO:85) CDRL3 sequence: QEWNYPYTF (SEQ ID NO:78) FR4 sequence: GGGTKLEIK (SEQ ID NO:86) 25 2.7.5 R3434 R3434 is commercially available from Dendritics, Inc. In-house sequence analysis of in-gel digested protein involved N-terminal sequence analysis using Edman degradation on an ABI Procise 494 automated protein sequencer (Applied Biosystems, Foster City, Ca., USA), peptide mass fingerprinting and MALDI-LIFT-MS/MS sequencing 30 on a Bruker Ultraflex Ill Maldi-TOF mass spectrometer and additional LC-ESI-MS/MS sequencing on a Bruker HCT+ ion-trap mass spectrometer (both from Bruker Daltonics, Bremen, Germany). The reverse engineered clone was named GR34, the sequence of which is below. 56 WO 2010/017468 PCT/US2009/053136 Rearranged VH of mAb GR34 EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKN LEWI GLINPYSGITS YNQNFKGKATLTVDKSSSTAYMELLNLTSEDSAVYYCARGDGNYWYFDVWGAGTTVTV SS (SEQ ID NO:90) 5 FR1 sequence: EVQLQQSGPELVKPGASMKISCKASGYSFT (SEQ ID NO:98) CDR1 sequence: GYTMN (SEQ ID NO:92) FR2 sequence: WVKQSHGKNLEWIG (SEQ ID NO:99) 10 CDR2 sequence: LINPYSGITSYNQNFK (SEQ ID NO:93) FR3 sequence: GKATLTVDKSSSTAYMELLNLTSEDSAVYYCAR (SEQ ID NO:100) CDR3 sequence: GDGNYWYF (SEQ ID NO:94) FR4 sequence: DVWGAGTTVTVSS (SEQ ID NO:101) 15 Rearranged Vk of mAb GR34 EliLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARF SGSGSGTSYSLTISSMEAEDAAYYCQYWNYPYTFGGGTKLEIK (SEQ ID NO:91) FR1 sequence: EIILTQSPAITAASLGQKVTITC (SEQ ID NO:102) 20 CDR1 sequence: SASSSVSYMHW (SEQ ID NO:95) FR2 sequence: YQQKSGTSPKPWIY (SEQ ID NO:103) CDR2 sequence: EISKLAS (SEQ ID NO:96) FR3 sequence: GVPARFSGSGSGTSYSLTISSMEAEDAAYYC (SEQ ID NO:104) CDR3 sequence: QYWNYPYTF (SEQ ID NO:97) 25 FR4 sequence: GGGTKLEIK (SEQ ID NO:105) 2.8 Identification of 9B7 epitope by peptide ELISA The epitope of the anti-hCD127 antibody 9B7 was determined by peptide ELISA 30 as before (1.2). The results of this mapping are shown in Table 3. 57 WO 2010/017468 PCT/US2009/053136 Table 4. shows three positive regions of hCD127 identified by peptide ELISA using clone 9B7 Region 1 35 LDDYSFSCYSQLEVN 49 SEQ ID NO: 20 Region 2 84 NFRKLQEIYFIETKKFLLIGKS SEQ ID NO: 21 105 Region 3 171 QEKDENKWTH 180 SEQ ID NO: 22 2.9 Determination of antibody binding epitope of 6C5 and R.34.34 by surface plasmon 5 resonance (BlAcore) 15 mers with 7 to 8 overlapping peptides of CD127 ECD were synthesized by Shanghai Science peptide Biology Technology, and by GL Biochem (Shanghai) Ltd. All peptides were prepared by continuous-flow solid phase peptide synthesis. The peptides 10 were then biotinylated at the N-terminus of the peptide with a spacer Acp between the peptide and the biotin moiety, i.e., biotin-Acp-peptide. The binding of anti-CD127 antibodies to 15 mers synthesized peptide of human CD127 was assessed using a Biacore T100 system (GE Healthcare). Briefly, anti-CD127 antibody was immobilized on a CM5 biosensor chip with a final level of -1000 RU 15 (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 7.4 (consisting of 10 mM HEPES, 0.15 M sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was activated/deactivated using EDC/NHS/ethanol amine. 1 M peptides were injected for 120s at a flow rate of 1OuL/min. Data were analyzed using the Biacore 20 evaluation software package. The runs were carried out at 250C. Table 5 shows positive region for 6C5 and R34.34 antibody identified by BlAcore 6C5 Region 1 65 NTTNLEFEICGALVE 79 SEQ ID NO: 45 R34.34 Region 1 65 NTTNLEFEICGALVE 79 SEQ ID NO: 106 Region 2 80 VKCLNFRKLQEIYFI 94 SEQ ID NO: 107 Region 3 95 ETKKFLLIGKSNICV 109 SEQ ID NO: 108 Region 4 155 LQKKYVKVLMHDVAY 169 SEQ ID NO: 109 Region 5 162 VLMHDVAYRQEKDEN 176 SEQ ID NO: 110 58 WO 2010/017468 PCT/US2009/053136 2.10 Prediction of epitopes by biopanning phage peptide display To predict the epitope of the anti-hCD127 antibodies, phage display was carried out as before (Section 1.3) on antibodies 9B7, 6C5, R3434, 6A3 and A1 1. 5 2.10.1 9B7 Phage peptide consensus sequence motif or mimotopes identified from the 2 random peptide libraries predicted discontinuous epitopes of mAb 9B7 (Table 4). 10 Table 6 shows three positive regions of hCD127 identified by phage peptide library using clone 9B7 Region 1 80 VKCLNFRKLQEIYFI 94 (SEQ ID NO:23) Region 2 95 ETKKFLLIGKSNICV 109 (SEQ ID NO:24) Region 3 170 RQEKDENKWTHVNLS 184 (SEQ ID NO:25) Summary of epitope mapping by phage peptide display and peptide ELISA: three regions 15 were identified as potential epitopes of CD127 for 9B7 monoclonal antibody, as shown below: position 35 LDDYSFSCYSQLEVN 49 (SEQ ID NO:26); position 84 NFRKLQEIYFIETKKFLLIGKS 105 (SEQ ID NO:27) position 139 YREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTH 20 180 (SEQ ID NO:28) 2.10.2 6C5 Phage peptide mimotopes identified from the 2 random libraries predicted 2 possible discontinuous epitopes of antibody 6C5. 25 Table 7 shows 6C5 epitope regions identified by phage peptide library Region 1 55 LTCAFEDPD 63 (SEQ ID NO:46) Region 2 209 PDHYFKGFWSE 219 (SEQ ID NO:47) Summary of epitope mapping by phage peptide display and peptide BlAcore: three regions were identified as potential epitopes of CD127 for 6C5, as shown below: 30 Position 55 LTCAFEDPD 63 (SEQ ID NO:48) Position 65 NTTNLEFEICGALVE 79 (SEQ ID NO:49) 59 WO 2010/017468 PCT/US2009/053136 Position 209 PDHYFKGFWSEE 219 (SEQ ID NO:50) 2.10.3 R.34.34 5 Table 8 shows R34.34 epitope regions identified by phage peptide library Region 1 65 NTTNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGK 104 (SEQ ID NO:111) Region 2 153 SHLQKKYVKVLMH 165 (SEQ ID NO:1 12) Region 3 211 HYFK 214 (SEQ ID NO:113) Summary of epitope mapping by phage peptide display and peptide BlAcore: three regions were identified as potential epitopes of CD127 for R34.34, as shown below: Position 65 NTTNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGK 104 (SEQ 10 ID NO:114) Position 153 SHLQKKYVKVLMH 165 (SEQ ID NO:115) Position 211 HYFK 214 (SEQ ID NO:116) 2.10.4 6A3 15 Phage peptide consensus sequence motif or mimotopes identified from the 2 random peptide libraries predicted discontinuous epitopes of mAb 6A3. Table 9 shows 6A3 epitope regions identified by phage peptide libraries Region 1 66 TTNLEFEICGAL 77 (SEQ ID NO:67) Region 2 91 IYFIETKKFLLIGKSNICV109 (SEQ ID NO:68) Region 3 152 TSHLQKKYVKVL 163 (SEQ ID NO:69) Region 3 212 YFKGFWSEWSP 222 (SEQ ID NO:70) 20 It is postulated that these regions may be closely neighbouring regions within an important effector site of CD127, potentially involved in the site of IL-7 binding. 2.10.5 1A11 Phage peptide consensus sequence motif or mimotopes identified from the 2 25 random peptide libraries predicted discontinuous epitopes of mAb A1 1. 60 WO 2010/017468 PCT/US2009/053136 Table 10 shows 1A11 epitope regions identified by phage peptide libraries Region 1 79 EVKCLNFRKLQEIYFIETKKF 99 (SEQ ID NO:87) Region 2 150 FNTSHLQ 156 (SEQ ID NO:88) Region 3 207 SIPDHYFKGFWSEW 220 (SEQ ID NO:89) It is postulated that these regions may be closely neighbouring regions within an important effector site of CD127, potentially involved in the site of IL-7 binding. 5 2.11 Antibody binding neutralizing assay by BlAcore The assay was carried out using a BlAcore T100 system (GE Healthcare) with a reaction temperature of 250C. Recombinant human IL-7 was immobilized on a CM5 biosensor chip 10 with a final level of -500 RU (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 7.4 (consisting of 10 mM HEPES, 0.15 M sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was blank immobilized using EDC/NHS/ethanol amine. 10 pg/mL recombinant human CD127 ECD was mixed with various concentrations 15 of anti-CD127 antibodies in separate vials and allowed to incubate for 30 min at 4C. These mixtures, as well as 10 pg/mL recombinant human CD127 ECD alone, were then injected over the chip surface for 30s at 10 pL/min. After each injection the sensor chip surfaces were regenerated with 10 mM Glycine-HCI, pH 2.0. At 100 ug/ml antibody 6C5 completely inhibited CD127-ECD binding to IL-7 on the sensor chip. The results for 6C5 20 are shown in Figure 13. The assay was repeated for 6A3, using a Biacore T100 system (GE Healthcare) with a reaction temperature of 250C. Recombinant human IL-7 was immobilized on a CM5 biosensor chip with a final level of -1000 RU (response units) using the standard amine coupling kit and procedure. HBS-EP buffer pH 7.4 (consisting of 10 mM HEPES, 0.15 M 25 sodium chloride, 3 mM EDTA and 0.005% v/v surfactant P20) was used as running buffer. Sensograms were run against a reference cell that was blank immobilized using EDC/NHS/ethanol amine. 10 pg/mL recombinant human CD127 ECD was mixed with various concentrations of anti-CD127 antibodies in separate vials and allowed to incubate for 1 hr at 40C. These mixtures, as well as 1Opg/mL recombinant human CD127 ECD 30 alone, were then injected over the chip surface for 60s at lOpL/min. After each injection the sensor chip surfaces were regenerated with 10 mM Glycine-HCI, pH 2.0. At 10pg/ml antibody 6A3 completely inhibited CD127-ECD binding to IL-7 on the sensor chip. The 61 WO 2010/017468 PCT/US2009/053136 results are shown in Figure 16A and 16B. Inhibition ratio calculated as follows: Inhibition ratio = 1 - RU (sample) / RU (ECD). 2.12 IL-7 competition by FACS 5 CHO-CD127 cells were prepared and washed by cold Dulbecco's Phosphate Buffered Saline (DPBS) for 3 times and 2 X 10 5 cells were then incubated with 2pg/mL recombinant IL-7 in separated vials at 40C for 30 min. After the incubation, anti-CD127 antibodies were added and the incubation continued for additional 30 min in 4% FCS in 10 DPBS (FACS buffer). Afterward cells were washed in FACS buffer 3 times and stained with anti-mouse IgG ALEXA488 secondary antibody at 1:2000 dilution (Invitrogen Inc. #13-A11017). The cells were then washed 3 times in in FACS buffer and were analyzed in LSR || (BD Biosciences Inc.). While increasing concentration of IL7, the binding of 6A3, R34.34 or 6C5 to CHO 15 CD127 is decreased, indicating binding competition of these antibodies with IL-7 to CD127 expressed on CHO cells (Figure 14 shows the result obtained with 6C5, Figure 17 shows the result obtained with 6A3). The effect on 9B7 binding was less marked, indicating that 9B7 had less effect on IL-7 competition in this assay. 20 2.13 Antibody binding cross-competition assay by FACS CHO-CD127 cells were prepared and washed by cold DPBS for 3 times. Fluorescence labelled anti-CD127 antibody (BD Biosciences Inc #552853) was diluted in FACS buffer 25 and mixed with various concentrations of non-labelled same antibody, or mixed with testing anti-CD127 antibodies, R34.34 and 6C5. The antibody mixtures were then incubated with the CHO-CD127 cells for 30 min at 40C. After washing in FACS buffer for 3 times, binding of fluorescent labelled BD antibody is measured in LSR || (BD Biosciences Inc.). The results showed that, in addition to unlabeled BD antibody, mAb 30 R34.34 and 6C5 competed for binding with the labelled BD antibody, indicating antibodies BD, R34.34 and 6C5 recognize a similar epitope on CD127 expressed on CHO cells. (Figure 15). Example 3: Treatment effect of IL-7R antibody in EAE 35 The potential for the murine antibodies described in Example 1, to treat MS, was 62 WO 2010/017468 PCT/US2009/053136 assessed in a mouse EAE model. This experiment has been repeated on multiple occasions; a single representative example is described below. Methods 5 3.1 Induction and evaluation of experimental autoimmune encephalomvelitis (EAE) Male C57BL/6 mice (6-8 wk; Shanghai Laboratory Animal Center, Chinese Academy of Sciences, Shanghai, China) were immunized s.c. with a synthetic peptide (300 pg) of myelin oligodendrocyte glycoprotein (MOG residues 35-55). Immunization 10 was performed by mixing MOG peptide in complete Freunds adjuvant (CFA, containing 5 mg/ml heat-killed H37Ra strain of Mycobacterium tuberculosis (Difco Laboratories)). Two hundred nanograms of pertussis toxin (List Biological Laboratories) in PBS was administered i.v. on the day of immunization and 48 h later. For the treatment protocol, a commercially available anti-mouse CD127 mAb was 15 used (BD Bioscience, rat anti-mouse CD127 SB/14, Cat. #550426), a second monoclonal antibody which neutralized IL-7 alone was also tested (R&D systems). The test antibodies or control IgG was administered at 200 pg per mouse i.p. every other day from day 10 onwards till a total of 5 injections. In some experiments, control IgG was replaced by PBS as for the control group. Mice were weighed and examined daily for disease symptoms. 20 They were scored for disease severity using the EAE scoring scale: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of 1 or 2 hind limbs); 3, paraplegia (complete paralysis of 2 hind limbs); 4, paraplegia with fore limb weakness or paralysis; 5, moribund state or death. 25 3.2 Histoloqy and lmmunohistochemistry Tissues for histological analysis were removed from mice 21 days after immunization and immediately fixed in 4% paraformaldehyde. Paraffin-embedded 5- to 10-pm sections of spinal cord were stained with Luxol fast blue or H&E and then examined by light microscopy. For immunofluorescence staining of CD4+ T cells and 30 CD11 b+ monocytes/macrophages, spinal cords were removed from mice, perfused with PBS, and incubated in 30% sucrose at 4'C overnight. The tissue was subsequently dissected and embedded in optimal cutting temperature (OCT) compound. Frozen specimens were sectioned at 7 pm with a cryostat, and the sections mounted upon slides, air dried, and fixed for 10 min with 100% acetone. After blocking with 3% BSA, the 35 sections were incubated overnight with primary rat anti-mouse CD4 or CD1 1 b Abs (BD Biosciences), which were then labeled with Cy3 AffiniPure donkey anti-rat IgG (Jackson 63 WO 2010/017468 PCT/US2009/053136 ImmunoResearch Laboratories) and examined by immunofluorescence microscopy (Nikon). Isotype-matched Abs were used as negative controls. The degree of demyelination, infiltration of leukocytes, CD4+ T cells and CD11b+ monocytes/ macrophages was quantified on an average of 3 spinal cord transverse sections per 5 mouse for a total of 5 mice per group using a previously published procedure. 3.3 Proliferation and cytokine assays In proliferation assays, splenocytes (5 x10 5 per well) derived from EAE mice were cultured in triplicate in RPMI 1640 in 96-well plates. Cells were cultured in the presence 10 or absence of the MOG peptide (20 pg/ml) or Con A (2 pg/ml) at 37'C in 5% C02 for 72 h. Cells were pulsed with 1 pCi of [3H] thymidine during the last 16 -18 h of culture before harvest. [3H] thymidine incorporation in cpm was measured by a MicroBeta counter (PerkinElmer). For cytokine measurements, supernatants were collected from cell culture at 48 h 15 and diluted for the measurement of IL-1a, IL-2, IL-4, IL-5, IL-6, IL-17, IFN-y, IL-23 by using Mouse TH1/TH 2 Flowcytomix Multiplex kit and Mouse IL-23 Flowcytomix Simplex kit (Bender MedSystem) according to the manufactures instruction. Briefly, culture supernatants were incubated with the beads mixture coated with capture antibodies and the biotin-conjugated second antibodies mixture at room temperature for 2 hours in dark, 20 PE-labeled streptavidin was added and incubated for 1 hour at room temperature in dark. Data was collected in BD LSR || (Becton Dickinson) and analyzed with BMS FlowCytomix software (Bender MedSystem). Mouse TGF-p and IL-21 were measured by Duoset ELISA kit (R&D Systems) according to the manufacturer's instructions. A standard curve was performed for each plate and used to calculate the absolute concentrations of the 25 indicated cytokines. 3.4 Immunoblot analysis Protein extracts were loaded onto 10% or 12% SDS-polyacrylamide gels and subjected to electrophoresis. Immunoblot analysis was performed by initial transfer of 30 proteins onto Immobilon-P membrane (Millipore) using a Mini Trans-Blot apparatus (Bio Rad). After 2 h of blocking, the membranes were incubated overnight at 4'C with specific primary Abs against P-JAK1, JAK1, P-AKT, AKT, P-Stat3, Stat3, P-Stat5, Stat5, Bcl-2, Bcl-xL, Bim, Bad, P-Bad (All the aforementioned antibodies are from Cell Signal), MCL-1 (Bio-legend), Bax (BD Bioscience), RORyt (Abcam), Foxp3 (Santa Cruz Biotechnology), 35 Actin (Santa Cruz Biotechnology) respectively. After washing and subsequent incubation with a goat anti-rabbit (Sigma-Aldrich) or goat anti-rat Ab (Jackson ImmunoResearch) 64 WO 2010/017468 PCT/US2009/053136 conjugated with HRP for 1 h at room temperature and extensive washing, signals were visualized with ECL substrate (Pierce). 3.5 cDNA array analysis 5 The expression profile of selected genes related to apoptosis and JAK-STAT signaling pathway was analyzed by using a validated cDNA array system (GEArray S Series, SuperArray Bioscience detailed gene list can be found at the manufacturer's website: www.superarrav.com/qene array product/HTML/MM-602.3.html). Briefly, splenocytes were isolated from naive or day 21 EAE mice treated with anti-CD127 mAb 10 or PBS. CD4+ CD25+ Treg and CD4+CD25- non- Treg cells were obtained by magnetic bead separation (Mitenyi Biotec). Total RNA was extracted using Trizol Reagent (Invitrogen). Three micrograms of total RNA were reverse transcribed into biotin-16 deoxy-UTP-labeled single-strand cDNA using an AmpLabeling-LPR Kit (SuperArray). After prehybridization, membranes were hybridized with biotin-labeled sample cDNA and 15 incubated with alkaline phosphatase-conjugated streptavidin (Chemiluminescent Detection kit; SuperArray) to visualize the signal. The results were analyzed using the GEArray Expression Analysis Suite (SuperArray). The results are representative of three experiments using independent splenocyte preparations. 20 3.6 Apoptosis analysis Analysis for apoptosis was performed using an annexin V-FITC apoptosis detection kit (BD Biosciences), splenocytes derived from EAE mice were washed and incubated with 5 pl of annexin V-FITC and 5 pl of 7-AAD for 15 min at room temperature. Stained cells were analyzed subsequently using a FACS LSRII instrument (BD) within 1 25 h. 3.7 Isolation of mononuclear cells from mouse CNS tissue Mononuclear cells were prepared from brain and spinal cord using gradient centrifugation. In brief, mice were perfused with 30 ml PBS to remove blood from internal 30 organs. The dissociated brain and spinal cord tissue were grinded and filtered through a 70pm cell strainer. Resulting cell solution was centrifuged in a Percoll gradient. Mononuclear cells at the interface between two gradients (37% and 70% Percoll, Pharmaica) were collected, washed by centrifugation with medium, and then submitted to FACS analysis. 35 65 WO 2010/017468 PCT/US2009/053136 3.8 Isolation of CD4+ T cells Spleens of naive mice were removed and dispersed into single cell suspensions. For purification of naive T cells, CD4' T cells were first purified using CD4 microbeads (Miltenyi) from spleen and lymph nodes of naive mice. The resulting cells were labeled 5 subsequently with CD44, CD62L and CD25 antibodies and further purified for the CD44'OCD62LhiCD25 population by FACS sorting (FACSAria 1l, Becton Dickinson). To get CD4+CD 25 hi and CD4+CD25- T cells, single cell suspensions were incubated with FITC-labelled anti-CD4 antibody and PE-labeled anti-CD25 antibody (BD Biosciences) on ice for 30 min. CD4+CD 2 5 hi and CD4CD25- T cells were sorted by a FACSAria 10 instrument (Becton Dickinson). Similar approaches were employed to isolate human CD4*CD25* and CD4*CD25- T cells. CD4' T cells were first purified from PBMCs using a CD4' No-touch T cell isolation kit (Miltenyi Biotec), and CD4*CD25- T cells were isolated by negative selection using anti-CD25 microbeads (Miltenyi Biotec). The purity of CD4*, CD4*CD25*, and CD4*CD25- T cell fractions was always greater than 95%. 15 3.9 Induction of TH1 7 , TH1 and T. Naive mouse CD4+ T cells were plated in 96-well flat-bottomed plates (Costar) at a density of 1x 106 cells/ ml. Cells were stimulated with plate-bound anti-CD3 Ab (5 pg/ml; BD Bioscience) and anti-CD28 Ab (5 pg/ml; BD Bioscience) in complete medium. 20 T cells were cultured in TH1 conditions {recombinant IL-12 (10 ng/ml; eBioscience) lus anti-IL-4 (10 pg/ml; BD Bioscience)}, or TH1 7 conditions {TGF-p1 (1 ng/ml; R&D Systems), IL-23 (10 ng/ml; R&D Systems) and IL-6 (10 ng/ml; eBioscience) plus anti-IFNy (10 pg/ml; BD Bioscience) and anti-IL-4(10 pg/ml)}for4 days. To induce/convert CD4*CD25* Treg from CD4*CD25- T cells, purified human or 25 mouse CD4*CD25- T cells were cultured at 2 x 106 cells/ml with TGF-p1 (10 ng/ml) and IL-2 (50 IU/ml, R&D Systems) in the presence of coated anti-CD3 antibody (5 pg/ml) and 5 pg/ml anti-CD28 antibody for 4 days. In some cases, medium was washed out from the aforementioned culture systems and cells were then cultured in fresh medium for 1 h or 48 h in the presence or absence of IL-7 (10 ng/ml). To differentiate human TH1 7 cells, 30 total human CD4+ cells were stimulated in anti-CD3 and anti-CD28 in the presence of IL 1p, IL-6, and IL-23 for six days. IL-7, IL-2, and antibodies were added on day 3 to the differentiation system. 66 WO 2010/017468 PCT/US2009/053136 3.10 Flow cytometric analysis For surface staining of CD4, CD25, CD8, B220 and CD127, cells were resuspended in PBS containing 1% BSA (Sigma-Aldrich) and 0.1% sodium azide and incubated with fluorochrome-conjugated antibodies to the indicated cell surface markers 5 (BD Bioscience or eBioscience) for 30 minutes on ice. For intracellular cytokine staining, freshly isolated mononuclear cells from lymph nodes, spleens and CNS of EAE mice or in vitro cultured cells were re-stimulated for 5 h with PMA (20 ng/ml) and lonomycin (1 pM) in the presence of GolgiPlug (1:1000 diluted; BD Bioscience). The cells were surface stained with fluorescently labeled antibodies, resuspended in Fixation/Permeabilization 10 solution (BD Bioscience), and stained for intracellular cytokines according to the manufacturer's instructions. Particularly, for IL-7 intracellular staining, cells were firstly incubated with antibodies against mouse CD16/CD32 (BD Bioscience) for 30 min at 40C and followed by fixation/permeabilization using BD Bioscience solution, cells were then stained with goat anti-mouse IL-7 IgG (R&D Systems) or goat IgG (R&D Systems) as 15 primary antibodies and Alexa Fluor@ 488 donkey anti-goat IgG (Jackson Immunol) as a secondary antibody. Bcl-2 intracellular staining was performed with the same protocol but without the PMA and lonomycin stimulation. As for intracellular staining of Foxp3, cells were fixed and permeabilized with Foxp3 staining buffer (eBioscience). Permeabilized cells were stained with PE or FITC-conjugated anti-human or anti-mouse 20 Foxp3 mAbs (0.5 pg/1 06 cells; eBioscience). For intracellular staining of phosphorylated yes, cells were fixed for 10 min at 37 'C with 2% (wt/vol) paraformaldehyde, made permeable for 30 min on ice with 90% (vol/vol) methanol, and stained for anti phosphorylated Stat5 (BD Bioscience) staining. Flow cytometric analysis was performed on BD LSR || (Becton Dickinson) instruments and results were analyzed using FlowJo 25 software (Tree Star Inc.). 3.11 Statistical analysis Differences in the expression of genes between the groups were analyzed by the Mann-Whitney U test. Two-tailed Student's t test was used to analyze the differences 30 between the groups. One-way ANOVA was initially performed to determine whether an overall statistically significant change existed before using the 2-tailed paired or unpaired Student's t test. A P value of less than 0.05 was considered statistically significant. Results 35 3.12 Amelioration of EAE by IL-7R or IL-7 Antaqonism 67 WO 2010/017468 PCT/US2009/053136 As shown in Figure 5, when administered three times from Day 10 onwards, anti CD127 antibody treatment markedly altered the clinical course of EAE by reducing the disease severity compared to an isotype control (Figure 5A). The treatment regimen resulted in a marked reduction in disease severity accompanied by decreased 5 inflammation and demyelination in affected spinal cord compared to that of control mice. Splenocytes obtained from treated mice exhibited significantly decreased T cell reactivity to MOG but not non-specific T cell activation induced by ConA (Figure 5B). Noticeably, the treatment effect correlated with a selective reduction in the production of IL-17 among other inflammation-related cytokines in MOG-reactive T cells (Figure 5C), and in 10 percentage of TH1 7 cells and to a lesser extent, TH1 cells in both spleen and spinal cord of treated EAE mice (Figure 5D). The absolute numbers of CNS-infiltrating TH1 7 cells were decreased by 10-fold in treated mice compared to those of control mice. In contrast, Treg cells increased reciprocally over the course of EAE (Figure 5D). There was differential expression of IL-7R in the three subsets (Figure 5E). 15 It was further evident that TH1 7 and TH1 cells seen after onset of EAE (day 12 or day 21 post-immunisation) were exclusively the CD44*CD62L- memory phenotype and susceptible to IL-7R antibody treatment (data not shown). Although CD4' T cell infiltration in spinal cord was markedly reduced, the absolute number and overall composition of peripheral CD4' and CD8' T cells and B220' B cells were not significantly altered (data 20 not shown). The results indicate that CD4' T cells of the memory phenotype in EAE were highly enriched for pathogenic TH1 7 and TH1 subsets and susceptible to IL-7R antagonism, which tilts the TH1 7 /TH1 to Treg ratio towards a new balance in treated EAE mice. An antibody against IL-7 also attenuated the EAE clinical scores (Figure 5F), 25 although not quite to the extent seen with the anti-CD127 antibody. Furthermore, as shown in Figure 6, CD127 was highly expressed in TH1 and TH1 7 cells derived ex vivo from spleen or spinal cord of EAE mice while the CD127 expression was significantly lower in Foxp3+ Treg. 30 3.13 The role of IL-7 in TH17 differentiation The in vivo development and function of pathogenic TH1 7 is a dichotomic process comprised of differentiation and survival and expansion. Pro-inflammatory cytokines such as IL-6, IL-1p and IL-21 are critical to TH1 7 differentiation and the initiation of autoimmune inflammation in EAE, while survival and expansion of TH1 7 cells is poorly understood and 35 may involve IL-23. 68 WO 2010/017468 PCT/US2009/053136 The inventors investigated whether IL-7/IL-7R signalling was associated with TH17 differentiation using purified naive CD4' T cells of the CD44'OCD62LhiCD2 5 - phenotype. The effect of IL-7 was examined by stimulating the resulting cells with CD3/CD28 antibodies in the presence and absence of TGF-p. Although IL-7 promoted TH17 5 differentiation when combined with TGF-p, the effect was moderate in magnitude compared to that of IL-6 and independent of IL-6 (Figure 7A), which correlated with marginal induction of STAT-3 phosphorylation and RORa expression by IL-7 (Figure 7B, Figure 7C). Similar to IL-6, IL-7 alone did not induce TH1 7 differentiation (data not shown). Given the moderate effect of IL-7 on TH1 7 differentiation, we addressed whether the 10 observed effect had in vivo significance in EAE. When administered before onset of EAE (injections at days 0, 2 and 4), the IL-7R antibody treatment did not affect the disease severity even though it slightly delayed the onset as compared to that in mice treated with control antibody (Figure 7D). The data collectively suggest that IL-7/IL-7R signalling is involved marginally in but not critically required for TH1 7 differentiation. 15 3.14 Selective inhibition of TH1 7 and TH1 cells in treated EAE mice and the role of CD127 antagonism in TH1 7 development We then examined the role of CD127 antibody in TH1 7 differentiation and maintenance/ expansion in both in vivo and in vitro experimental settings. As shown in 20 Figure 8A, the percentage of TH1 7 cells and y-interferon secreting TH1 cells, to a lesser degree, was decreased in splenocytes and CNS infiltrates in treated EAE mice compared to those of control mice while the levels of Foxp3+ Treg were significantly elevated (Figure 8B). The changes in the percentage of TH1 7 , TH1 and Treg in the course of EAE in both treated and control mice are presented in Figure 8C. In a separate in vitro experimental 25 setting, TH1 7 , TH1 and Treg were differentiated, respectively, from naive splenocytes using different induction protocols in the presence and absence of CD127 antibody. The result suggested that differentiation of TH1 7 and, to a lesser extent, TH but not Treg was inhibited when CD127 antibody was added in the onset of differentiation (Figure 9A). A similar effect of CD127 antibody on differentiated TH1 7 but not TH1 or Treg 30 was seen (Figure 9B). However, subsequent reruns of this protocol were unable to repeat this initial finding, suggesting that the role of IL-7/IL-7R signalling is only marginal in differentiation of TH1 7 cells. 69 WO 2010/017468 PCT/US2009/053136 3.15 IL-7 involvement in TH1 7 survival and expansion It was of interest to investigate whether IL-7 was required for TH1 7 differentiation. In this regard, initial results suggested that addition of IL-7 alone was found to increase the differentiation of TH1 7 and, to a lesser degree, TH1 but not Foxp3 in Treg when day 8 5 EAE MOG-specific T cells were cultured (Figure 10). However, as described herein (Section 3.17), further work revealed the dichotomic process of TH1 7 development, and suggested that the promotion of TH1 7 cells was not primarily a result of an increase in differentiation, but a result of an increase in TH17 expansion and survival, in which IL-7 plays a much more significant role. 10 3.16 Susceptibility of TH1 7 but not Tren to apoptosis induced by IL-7R antagonism We then investigated the mechanism underlying selective reduction and susceptibility of TH1 7 by an anti-CD127 antibody. As illustrated in Figure 11A, immunoblot analysis of CD4+ T cells derived ex vivo from treated or control EAE mice revealed that 15 anti-CD127 antibody treatment resulted in specific changes in signalling pathways related to JAK-STAT and apoptosis as characterized by down-regulation of phosphorylated JAK 1 and phosphorylated STAT-5 and markedly decreased levels of a key pro-apoptotic molecule, BCL-2, and increased activity of an anti-apoptotic molecule, BAX. The modulation of pro- and anti-apoptotic proteins correlated with increased apoptosis level in 20 CD4+ cells in antibody-treated mice. As shown in Figure 11B, CD127 antibody treatment led to markedly increased percentage of Annexin-V+ apoptotic cells among CD4+CD127+ T cells compared to that of CD4+CD127- T cells derived from treated EAE mice. It appears that differentiated TH1 7 cells derived from EAE mice underwent self initiated or programmed apoptosis that could be reverted by the addition of IL-7. The 25 process was abolished by pre-incubation of susceptible cells with an anti-IL-7R antibody but not a control antibody. IL-7 significantly altered the expression levels of BCL-2, which correlated reciprocally with the levels of Annexin-V* apoptotic cells (Figure 11 C). The observed effect of IL-7 was clearly mediated through STAT-5 and could be blocked by a STAT-5 specific inhibitor but not by a STAT-3 inhibitor (Figure 11D) or a 30 P13-K inhibitor (data not shown). The findings lend further support for the role of IL-7 as a critical survival signal for differentiated TH1 7 cells to expand by regulating STAT-5 phosphorylation and levels of anti- and pro-apoptotic proteins. 70 WO 2010/017468 PCT/US2009/053136 3.17 Effect of a neutralizing antibody to human IL-7R on human TH1 7 Cells Our studies in the mouse experimental system showed that TH1 7 development is a two-step process; "Step 1" being TH precursor cell differentiation, and "Step 2" being TH1 7 survival/expansion. These two processes are controlled by different cytokines, the 5 expression of which are further regulated by various transcription factors. Both processes contribute critically to the clinical outcome of autoimmune disease. TH1 7 differentiation is mainly induced by IL-6 through JAK/STAT-3 pathway. The role of CD127 antagonism in TH17 differentiation was further validated in a human experimental system. When blocking IL-7/IL-7R using an anti-CD127 antibody 10 according to the invention, TH1 7 differentiation was minimal affected as shown in Figure 12, indicating that IL-7 plays a minor role in this process. In contrast, our results showed that the major role of IL-7/IL-7R signalling in this two-step cell development process is in Step 2 - pathogenic TH1 7 cell survival and expansion. In this second step, the role of IL 7 is superior to IL-23 through the JAK/STAT-5 pathway. When anti-human IL-7R mAb 15 was given after cells had already committed to TH1 7 cells, the cells are susceptible to apoptosis as shown in Figure 22. The study provides compelling evidence for a novel role of IL-7/IL-7R signalling in pathogenic TH1 7 cell development and functions in EAE and lends strong rationale for IL-7R antagonism as a potential treatment for MS and other autoimmune conditions. 20 3.18 Inhibition of IFNy production by IL-7 stimulated PBMC PBMCs were initially screened and selected on the basis of a positive result with antibody R34.34 (Dendritics Inc). Fresh or thawed PBMCs were plated at 2x105 cells/well in 96 well in RPMI 1640 containing 10% FBS. Purified testing antibody 6C5, 25 positive control antibody R34.34 (Dendritics Inc) and anti-human IL-7 (R&D), plus isotype control antibody mouse IgG1 (R&D) were incubated at 1Opg/ml and 1OOpg/ml with cells at 370C for 30 minutes before 10ng/ml IL-7 was supplemented. Cells briefly treated with IL-7 served as negative control while non-treated cells as background. 2pg/ml soluble anti CD3 and anti-CD28 (eBiosciences) were added to all conditions and the plate was 30 incubated for additional 24 hours at 370C with 5% C02. IFN-y level in culture supernatant was analyzed by human IFN-y ELISA (human IFN-y ELISA kit, eBiosciences). Under these condition, mAb 6C5 and antibody R34.34 inhibited IL-7 induced IFNy production (Figure 18) 71 WO 2010/017468 PCT/US2009/053136 3.19 Inhibition of 1L7 stimulated IL7-receptor signalled Stat5 phosphorVlation To screen for antibodies with the ability to block signaling functions of CD127, cryopreserved PBMCs were thawed rapidly and plated in RPMI 1640 medium containing 10% of FBS the night before the functional test. Test sample antibodies and positive 5 control antibody (R34.34, Dendritics Inc #DDX0700; BD anti-CD127, BD Biosciences Inc #552853) were prepared in 3 fold serial dilution starting from a top concentration of 120ug/ml, and added to 2x10 5 PBMC cells for 30mins at 370C before stimulation with IL-7 at 1ng/ml for 15mins at 371C. The cells without antibody and IL7 treatment were used as background control. The cells treated with 1L7 but not with antibody samples were used 10 as full activity control. Cells after treatment were lysed by lysis buffer (PerkinElmer #TGRS5S500) for 5mins at 371C and the lysates were incubated with Reaction Buffer plus Activation Buffer mix (PerkinElmer #TGRS5S500) containing AlphaScreen@ Acceptor beads (PerkinElmer #6760617C) for 2 hours at room temperature. After that, Dilution buffer (PerkinElmer #TGRS5S500) containing AlphaScreen@ Donor beads 15 (PerkinElmer #6760617C) were added and incubated for another 2 hours. Luminescence (RFU) from AlphaScreen beads were analyzed on Envision with its default alphascreen mode (top read; Ex 680nm; Em 570nm). Results for testing samples were converted to relative activity based on the following formula: 20 Relative activity (%) = (RFU(sample) - RFU(background control)) / (RFU(full activity control)-RFU(background control)) The results of this calculation are shown in Figure 19. 25 CCF-CEM cells were cultured in growth medium (RPM11640, 10% FBS, 100U/ml Penicillin, 100ug/ml Streptomycin, 1mM Sodium Butyrate) and treated with luM Dexamethasone (Sigma #D4902) overnight for 1L7 receptor induction before the experiment. Test sample antibodies and positive control antibody (R34.34, Dendritics Inc #DDX0700; BD anti-CD127, BD Biosciences Inc #552853) were prepared in 3 fold serial 30 dilution starting from a top concentration of 120ug/ml, and added to 2x10 5 CCF-CEM cells for 30mins at 371C before stimulation with IL-7 at 1ng/ml for 15mins at 371C. The cells without antibody and 1L7 treatment were used as background control. The cells treated with 1L7 but not with antibody samples were used as full activity control. Cells after treatment were lysed by lysis buffer (PerkinElmer #TGRS5S500) for 5mins at 371C and 35 the lysates were incubated with Reaction Buffer plus Activation Buffer mix (PerkinElmer #TGRS5S500) containing AlphaScreen@ Acceptor beads (PerkinElmer #6760617C) for 2 72 WO 2010/017468 PCT/US2009/053136 hours at room temperature. After that, Dilution buffer (PerkinElmer #TGRS5S500) containing AlphaScreen@ Donor beads (PerkinElmer #6760617C) were added and incubated for another 2 hours. Luminescence (RFU) from AlphaScreen beads were analyzed on Envision with its default alphascreen mode (top read; Ex 680nm; Em 5 570nm). Results for testing samples were converted to relative activity based on the following formula: Relative activity (%) = (RFU(sample) - RFU(background control)) / (RFU(full activity control)-RFU(background control)) 10 The results are shown in Figure 20. The experiment was essentially repeated, for antibody 6A3, as follows. Fresh PBMCs were suspended in serum free RPMI 1640 medium. Test sample antibodies and positive control antibody (6A3 and R34.34, Dendritics Inc #DDX0700) were diluted to 15 achieve final concentrations from 20 ug/ml to 0.01 ug/ml in the culture and were added to 1x10 6 PBMC cells per sample. PBMCs were incubated with antibodies for 50mins at 370C before stimulation with IL-7 at 1ng/ml for 15mins. For intracellular staining of phosphorylated STAT5, cells were fixed for 10 min at 37 'C with 1% (wt/vol) paraformaldehyde, made permeable for 30 min on ice with 90% (vol/vol) methanol, and 20 stained for anti-phosphorylated Stat5 (BD Bioscience) staining. Flow cytometric analysis was performed on BD LSR || (Becton Dickinson) instruments and results were analyzed using FlowJo software (Tree Star Inc.). The cells without antibody and 1L7 treatment were used as background control. The cells treated with 1L7 but not with antibody samples were used as full activity control. 25 Figure 21 shows the inhibition of IL-7-induced P-STAT5 relative to no antibody control at increasing concentrations of R34.34 and 6A3. 3.20 Inhibition of IL-7 induced IL-17 production in differentiated T cells CD4+ cells from six donors were isolated according to the manual (#130-091-155, 30 Miltenyi). Approximately 1x106/ml of the CD4+ cells in 100 ul were mixed with equal volume of 2x TH1 7 medium (2pg/ml anti-CD28 + 10pg/ml anti-IFNy + 10pg/ml anti-IL-4 + 12.5ng/ml IL-1R + 20ng/ml IL-23 + 50ng/ml IL-6) and cultured in 371C with 5% C02 for 5 days. Treatment by the various cytokines and growth factors in the TH1 7 medium preferentially differentiated the CD4+ cells into TH1 7 cells. CCR6+ cells from the 35 differentiated cultured cells at day 5 were sorted using BD FACS SORP Aria //. The CCR6+ cells were then adjust to 2 x10 6 /ml for the IL-17 production assay. 73 WO 2010/017468 PCT/US2009/053136 To measure IL-17 level, 100pl of CCR6+ cells were pre-incubated with testing antibody for 1h at 37'C, and then mixed with 100pl of 20ng/ml IL-7. The cells were cultured for 3 days in 37'C with supplement of 5% C02. IL-17 level in 100pl of the culture supernatant were measured by FlowCytomix (Bender MedSystems). Table 11 5 shows the IL-7 and testing antibody (R34.34 and 6C5) concentrations used in generation of the results in Figure 22 (results from a single donor). R34.34 inhibited IL-17 production in IL-7 induced differentiated T cells in 6/6 donors; 6C5 inhibited IL-17 production in IL-7 induced differentiated T cells in 4/6 donors. 10 Table 11 CM 10ng/ml IL-7 1Opg/ml 50pg/ml 6C5 50pg/ml IgG R34.34 10ng/ml IL-7 10ng/ml IL-7 10ng/ml IL-7 The experiment was essentially repeated for antibody 6A3. CD4+ cells were isolated according to the manual (#130-091-155, Miltenyi) . Approximately 7x10 5 /ml of the CD4+ cells in 100 ul were mixed with equal volume of 2x TH1 7 medium (2pg/ml anti 15 CD28 + 10pg/ml anti-IFN-y + 10pg/ml anti-IL-4 + 12.5ng/ml IL-1B + 20ng/ml IL-23 + 50ng/ml IL-6) and cultured in 37'C with 5% C02 for 5 days. Treatment by the various cytokines and growth factors in the TH1 7 medium preferentially differentiated the CD4+ cells into Th17 cells. CCR6+ cells from the differentiated cultured cells at day 5 were sorted using BD FACS SORP Aria //. The CCR6+ cells were then adjusted to 2 x10 6 /Ml 20 for the IL-17 production assay. To measure IL-17 and IFN-y level, 100pl of CCR6+ cells from individual donors were pre-incubated with testing antibody for 1h at 37*C, and then mixed with 100pl of 20ng/ml IL-7. The cells were cultured for 3 days in 37'C with supplement of 5% C02. IFN-y and IL-17 levels in 100 ul of the culture supernatant were measured by 25 FlowCytomix (Bender MedSystems) at 24 h and 40 h, respectively. Table 12 shows the IL-7 and testing antibody concentrations used in generation of the results in Figure 23. The results are representative of 5/6 donors. 30 Table 12 CM 10ng/ml IL-7 10pg/ml R34.34 10pg/ml 6A3 10pg/ml IgG 10ng/ml IL-7 10ng/ml IL-7 10ng/ml IL-7 74 WO 2010/017468 PCT/US2009/053136 Conclusions The study described here provides the first immunological evidence supporting 5 the potential role of IL-7 and IL-7R in multiple sclerosis (MS). The present inventors have provided compelling evidence that IL-7/IL-7R signalling is critically required for survival and expansion of committed TH1 7 cells in both mouse and human systems, while its role in TH17 differentiation is not essential compared to that of IL-6. IL-7 or IL-7R antagonism administered after EAE onset significantly affect 10 the clinical course of disease. The inventors have therefore shown that IL-7 or IL-7R antagonism provides real therapeutic potential in the treatment of autoimmune diseases and inflammatory disorders in which pathogenic TH1 7 cells are implicated, particularly MS, and more particularly still the relapsing/remitting course of MS (RRMS). TH1 7 development and function is controlled chiefly by IL-6 through JAK/STAT-3 15 for TH1 7 differentiation and IL-7 through JAK/STAT-5 for TH1 7 maintenance. IL-7 not only provides a survival signal for pathogenic TH1 7 cells but directly induces in vivo TH1 7 cell expansion, critically contributing to sustained autoimmune pathology in EAE. As shown in this study, committed TH1 7 cells of the memory phenotype represent an in vivo pathogenic T cell subset and are susceptible to self-initiated or programmed 20 apoptosis. This process appears to be dependent on IL-7/IL-7R signalling through regulation of pro- and anti-apoptotic proteins, such as Bcl-2 and Bax, in susceptible TH17 cells. In this context, IL-7 serves as a critical survival signal that prevents differentiated TH1 7 cells from programmed apoptosis. Furthermore, increased IL-7 production and highly expressed IL-7R in pathogenic T cells as seen in the acute phase of autoimmune 25 diseases provide the milieu required for sustained T cell survival and expansion. It is proposed that interaction of IL-7 with its receptor induces aggregation of a and yc chains and activation of down-stream kinases. As a result, the process is likely to alter the cascade of kinase phosphorylation and create a docking site for STAT-5 phosphorylation, which is required for up-regulation of Bcl-2 and Mcl-1 and prevents mitochondria 30 mediated apoptosis by blocking Bim and Bad from activating Bax and Bak. Thus, it provides an explanation for the involvement of STAT-5 and its association with the anti apoptotic changes induced in pathogenic TH1 7 cells by IL-7. It is surprising that the in vivo effect on the immune system by IL-7R antagonism is highly selective in EAE, affecting TH1 7 cells and, to a lesser extent, TH cells 35 predominantly of the memory phenotype and sparing Treg cells. The inventors have shown that TH1 7 cell maintenance is affected by IL-7/IL-7R signalling. Under the same 75 WO 2010/017468 PCT/US2009/053136 experimental conditions, TH1 cells are altered in the in vitro but not in vivo system. The discrepancies may be explained by different cytokine milieu between the in vitro setting where exogenous IL-7 is added and in vivo micro-environment involving interplay of multiple cytokines. The selectivity for TH1 7 over Treg is readily explained by differential 5 expression of IL-7R, rendering TH1 7 cells susceptible and Treg cells resistant to IL-7R antagonism. This selectivity appears to play an important role in rebalancing the ratio of pathogenic TH1 7 cells and Treg cells by IL-7R antagonism in EAE and is attributable to the treatment efficacy. However, the discrepancies in the magnitude of IL-7-induced responsiveness and susceptibility to IL-7R antagonism between TH1 7 and TH1 could not 10 be simply explained by the expression of IL-7R as both subsets highly express IL-7R. The intrinsic expression and activity of SOCS-i is responsible for the discrepancies. That is, SOCS-1 naturally expressed in TH1 or experimentally induced in TH1 7 by IFN-y is attributable to dampened susceptibility to IL-7 or IL-7R antagonism as SOCS-1 acts as a repressor gene for STAT-5 required for IL-7 signalling. Thus, the selectivity for TH 7 cells 15 of the memory phenotype appears to involve intrinsic requirement of these pathogenic cells for IL-7 to survive when activated in the course of EAE. This therapeutic specificity represents an obvious advantage over many other treatment modalities proposed in the autoimmune diseases that often affect a broad spectrum of the immune system/functions. The novel mechanism of action of IL-7/IL-7R signalling in TH1 7 cell survival and 20 expansion as discussed above provides powerful explanations for the treatment efficacy of IL-7R antagonism in EAE and therapeutic implications for human autoimmune diseases, such as MS. IL-7 neutralization or IL-7R antagonism is likely to have unique therapeutic advantages. On one hand, the treatment offers the selectivity that distinguishes pathogenic TH1 and TH1 7 cells from Treg and unrelated immune cells. On the 25 other hand, additional therapeutic advantages of IL-7R antagonism involve its selective effect on survival and expansion of differentiated TH1 7 as opposed to TH1 7 differentiation. Targeting, with an inhibitor of the IL-7/IL-7R pathway, the in vivo maintenance of committed TH1 7 versus TH1 7 differentiation may be more efficacious in a therapeutic context. 76

Claims (37)

1. A method of treatment of an autoimmune disease or inflammatory disorder in a human subject, comprising administering to the subject an antagonist of at least one of 5 IL-7 receptor mediated TH1 7 expansion and IL-7 receptor mediated TH1 7 survival.

2. The method of treatment as claimed in claim 1, wherein the antagonist inhibits IL 7 induced IL-17 production by TH17 cells. 10

3. The method of treatment as claimed in claim 1 or 2, wherein the antagonist inhibits IL-7 induced IFN-y production by TH1 7 cells.

4. The method of treatment as claimed in claim 1, 2 or 3, wherein the antagonist inhibits IL-7 receptor mediated STAT-5 phosphorylation. 15

5. The method of treatment as claimed in any of claims 1, 2, 3 or 4, wherein the antagonist is a binding protein which specifically binds to IL-7 or to CD127.

6. The method as claimed in claim 5, wherein the binding protein specifically binds to 20 CD127 (SEQ ID NO:1).

7. The method as claimed in claim 6, wherein the binding protein inhibits the binding of IL-7 to IL-7R. 25

8. The method as claimed in claim 5, 6 or 7, wherein the binding protein binds to at least one amino acid within at least one peptide consisting of amino acid residues selected from the group consisting of: a) 41 to 63 (SEQ ID NO:117), b) 65 to 80 (SEQ ID NO:118), 30 c) 84 to 105 (SEQ ID NO:119), d) 148 to 169 (SEQ ID NO:120), and e) 202 to 219 (SEQ ID NO:121), of SEQ ID NO:1. 77 WO 2010/017468 PCT/US2009/053136

9. The method as claimed in claim 8, wherein the binding protein binds to at least one amino acid within each of peptides 65 to 80 (SEQ ID NO:118), 84 to 105 (SEQ ID NO:119), 148 to 169 (SEQ ID NO:120), and 202 to 219 (SEQ ID NO:121), of SEQ ID NO:1. 5

10. The method of treatment as claimed in claim 1, wherein the binding protein competitively inhibits binding of at least one of: (i) R34.34 (Dendritics Inc. #DDX0700), (ii) an antibody having heavy and light variable regions of 6A3 (SEQ ID NO:51 and 10 SEQ ID NO:52, respectively), and (iii) an antibody having heavy and light chain variable regions of 1A11 (SEQ ID NO:71 and SEQ ID NO:72, respectively), to human CD127 in an ELISA assay. 15

11. The method as claimed in any of claims 5 to 10, wherein the binding protein binds to CD127 with an affinity (KD) of 15nM or less as measured by surface plasmon resonance.

12. The method of treatment as claimed in any preceding claim, wherein the 20 antagonist is an antibody or a fragment thereof.

13. The method as claimed in claim 12, wherein the antibody comprises a heavy chain complementarity determining region 3 (CDRH3) of SEQ ID NO:55 or an analog thereof, or a heavy chain complementarity determining region 3 (CDRH3) of SEQ ID 25 NO:75.

14. The method of treatment as claimed in any preceding claim, wherein the autoimmune or inflammatory disease is associated with elevated levels of IL-17. 30

15. The method of treatment as claimed in any preceding claim, wherein the human subject has been determined to express an elevated level of IL-17 compared to a healthy human individual.

16. The method as claimed in claim 14 or 15, wherein the antagonist is administered 35 in an amount effective to reduce the level of IL-17 in the patient. 78 WO 2010/017468 PCT/US2009/053136

17. The method as claimed in claim 14, 15 or 16, wherein the level of IL-17 is measured in the serum of the patient.

18. The method of treatment as claimed in any preceding claim, wherein the 5 autoimmune disease is multiple sclerosis.

19. The method according to claim 18, wherein the patient has an raised TH1 7 count within their CD4' T cell population. 10

20. A method for treating multiple sclerosis in a patient comprising administering an antagonist of IL-7 or CD127 to said patient, wherein the patient is suffering from relapsing remitting multiple sclerosis.

21. A method of treating an autoimmune disease in a human subject, comprising 15 administering to the subject an antagonist of IL-7 or IL-7R in an amount effective to reduce the ratio of TH1 7 cells relative to TH cells.

22. A method of treating an autoimmune disease in a human subject, comprising administering to the subject an antagonist of IL-7 or IL-7R in an amount sufficient to 20 reduce the ratio of TH cells to Treg cells.

23. A method for the treatment of an autoimmune disease in a human subject, comprising administering to the subject an antagonist of IL-7 receptor mediated STAT-5 phosphorylation. 25

24. The method of treatment as claimed in claim 20, 21, 22 or 23, wherein the antagonist of IL-7 or IL-7R is a binding protein which specifically binds to CD127 or IL-7.

25. The method of treatment as claimed in any of claims 24, wherein the binding 30 protein is an antibody or antigen-binding fragment thereof which binds to at least one amino acid within at least one peptide consisting of amino acid residues: a) 41 to 63 (SEQ ID NO:117), b) 65 to 80 (SEQ ID NO:118), c) 84 to 105 (SEQ ID NO:119), 35 d) 148 to 169 (SEQ ID NO:120), and e) 202 to 219 (SEQ ID NO:121), 79 WO 2010/017468 PCT/US2009/053136 of SEQ ID NO:1.

26. An isolated human, humanised or chimeric antibody or an antigen-binding fragment thereof, wherein the antibody or fragment thereof binds to an epitope of human 5 CD127 that contains at least one amino acid residue within the region beginning at residue number 80 and ending at residue number 190.

27. The isolated antibody or antibody fragment as claimed in claim 26, wherein the antibody or fragment thereof binds to at least one amino acid within at least one peptide 10 consisting of amino acid residues: a) 41 to 63 (SEQ ID NO:117), b) 65 to 80 (SEQ ID NO:118), c) 84 to 105 (SEQ ID NO:119), d) 148 to 169 (SEQ ID NO:120), and 15 e) 202 to 219 (SEQ ID NO:121), of SEQ ID NO:1.

28. The isolated antibody or antibody fragment as claimed in claims 26 or 27, wherein the antibody or antigen-binding fragment thereof binds to human CD127 with an affinity 20 (KD) which is below 15nM, as measured by surface plasmon resonance.

29. An isolated binding protein, wherein the binding protein binds to CD127 and comprises a heavy chain complementarity determining region 3 (CDRH3) selected from the group consisting of SEQ ID NO:6, SEQ ID NO:33, SEQ ID NO:55 and SEQ ID NO:75 25 and analogs thereof.

30. The isolated binding protein as claimed in claim 29, wherein the binding protein comprises: 30 A: a heavy chain comprising the following CDRs or analogs thereof CDRH1: RYNVH (SEQ ID NO:4), CDRH2: MIWDGGSTDYNSALKS (SEQ ID NO:5), CDRH3: NRYESG (SEQ ID NO:6), and a light chain comprising the following CDRs or analogs thereof 35 CDRL1: KSSQSLLNSGNRKNYLT (SEQ ID NO:7), 80 WO 2010/017468 PCT/US2009/053136 CDRL2: WASTRES (SEQ ID NO:8), and CDRL3: QNDYTYPFTFGS (SEQ ID NO:9); or B: a heavy chain comprising the following CDRs or analogs thereof 5 CRDHI: AYWMS (SEQ ID NO:31), CDRH2: EINPDSSTINCTPSLKD (SEQ ID NO:32), CDRH3: RLRPFWYFDVW (SEQ ID NO:33), and a light chain comprising the following CDRs or analogs thereof CDRL1: RSSQSIVQSNGNTYLE (SEQ ID NO:34), 10 CDRL2: KVSNRFS (SEQ ID NO:35), and CDRL3: FQGSHVPRT (SEQ ID NO:36); or C: a heavy chain comprising the following CDRs or analogs thereof CRDHI: TDYAWN (SEQ ID NO:53), 15 CDRH2: YIFYSGSTTYTPSLKS (SEQ ID NO:54), CDRH3: GGYDVNYF (SEQ ID NO:55), and a light chain comprising the following CDRs or analogs thereof CDRL1: LASQTIGAWLA (SEQ ID NO:56), CDRL2: AATRLAD (SEQ ID NO:57), and 20 CDRL3: QQFFSTPWT (SEQ ID NO:58); or D: a heavy chain comprising the following CDRs or analogs thereof CDRH1: GYTMN (SEQ ID NO:73), CDRH2: LINPYNGVTSYNQKFK (SEQ ID NO:74), 25 CDRH3: GDGNYWYF (SEQ ID NO:75), and a light chain comprising the following CDRs or analogs thereof CDRL1: SASSSVTYMHW (SEQ ID NO:76), CDRL2: EISKLAS (SEQ ID NO:77), and CDRL3: QEWNYPYTF (SEQ ID NO:78). 30

31. The isolated binding protein as claimed in claim 29 or 30, which is an isolated humanized or chimeric antibody.

32. An antibody or antigen-binding fragment thereof which specifically binds to CD127, 35 wherein the antibody or fragment of an antibody competes for binding to human CD127 with one or more antibodies selected from the group consisting of: 81 WO 2010/017468 PCT/US2009/053136 a. an antibody having the following heavy chain variable region: EVKLLESGGGLVQPGGSLKLSCAASGFAFSAYWMSWVRQAPGKGLEWIGEINPDSSTI NCTPSLKDKFIISRDNAKNTLSLQMNKVRSEDTALYYCARRLRPFWYFDVWGAGTTVTV SS (SEQ ID NO:29), and the following light chain variable region: 5 DVLMTQTPLSLPVSLGDQASISCRSSQSIVQSNGNTYLEWYLQKPGQSPKLLYKVSNR FSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK (SEQ ID NO: 30); b. an antibody having the following heavy chain variable region: DVQLQESGPGLVKPSQSLSLTCTVTGYSITTDYAWNWIRQFPGNKLEWMGYIFYSGSTT 10 YTPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARGGYDVNYFDYWGQGTTLTVS S (SEQ ID NO:51), and the following light chain variable region: DIQMTQSPASQSASLGESVTITCLASQTIGAWLAWYQQKPGKSPQLLYAATRLADGVP SRFSGSGSGTKFSFKISSLQAEDFVSYYCQQFFSTPWTFGGGTKLEIK (SEQ ID NO:52); c. an antibody having the following heavy chain variable region: 15 EVQLQQSGPELLKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVT SYNQKFKGKATLTVAKSSSTAYMELLSLTSEDSAVYYCARGDGNYWYFDVWGAGTTVT VSS (SEQ ID NO:71), and the following light chain variable region: EIVLTQSPAITAASLGQKVTITCSASSSVTYMHWYQQKSGTSPKPWIYEISKLASGVPVR FSGSGSGTSYSLTISSMEAEDAAYYCQEWNYPYTFGGGTKLEIK (SEQ ID NO:72); and 20 d. an antibody having the following heavy chain variable region: EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKN LEWI GLINPYSGITS YNQNFKGKATLTVDKSSSTAYMELLNLTSEDSAVYYCARGDGNYWYFDVWGAGTTVTV SS (SEQ ID NO:90), and the following light chain variable region: Ell LTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARF 25 SGSGSGTSYSLTISSMEAEDAAYYCQYWNYPYTFGGGTKLEIK (SEQ ID NO:91); wherein the antibody is not R34.34 (Dendritics Inc. #DDX0700).

33. A human, humanised or chimeric antibody or an antigen binding fragment and/or derivative thereof which binds to CD127 and which comprises: 30 a heavy chain comprising the following CDRs or analogs thereof CDRH1: GYTMN (SEQ ID NO:92) CDRH2: LINPYSGITSYNQNFK (SEQ ID NO:93) CDRH3: GDGNYWYF (SEQ ID NO:94) a light chain comprising the following CDRs or analogs thereof 35 CDRL1: SASSSVSYMHW (SEQ ID NO:95) CDRL2: EISKLAS (SEQ ID NO:96) and 82 WO 2010/017468 PCT/US2009/053136 CDRL3: QYWNYPYTF (SEQ ID NO:97).

34. A method for treating an autoimmune disease or inflammatory condition, comprising administering to a patient who is suffering from the autoimmune disease or 5 inflammatory condition a binding protein, antibody or fragment thereof according to any of claims 26 to 33.

35. An antagonist of IL-7 receptor mediated TH1 7 expansion and/or survival for the treatment of an autoimmune disease or inflammatory disorder in a human subject. 10

36. An isolated binding protein, antibody or fragment thereof according to any of claims 26 to 33, for the treatment of an autoimmune or inflammatory condition.

37. A method for identifying antibodies suitable for use in the treatment of an 15 autoimmune disease or an inflammatory disease, the method comprising the steps of: screening a plurality of independent antibody populations to determine the ability of each antibody population to: i. inhibit the binding of IL-7 to IL-7R, ii. neutralise IL-7 induced STAT-5 phosphorylation, and/or 20 iii. inhibit the production of IL-17 by TH1 7 cells, and selecting those antibody populations which are able to inhibit the binding of IL-7 to IL 7R, inhibit IL-7 induced STAT-5 phosphorylation, and/or inhibit the production of IL-17 by TH1 7 cells. 83